<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28859112</article-id><article-id pub-id-type="pmc">5578482</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0183620</article-id><article-id pub-id-type="publisher-id">PONE-D-17-10388</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Response</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Response</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Inflammatory Diseases</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System</subject><subj-group><subject>Innate Immune System</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System</subject><subj-group><subject>Innate Immune System</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Developmental Biology</subject><subj-group><subject>Molecular Development</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Stem Cells</subject><subj-group><subject>Hematopoietic Stem Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Simulation and Modeling</subject><subj-group><subject>Mathematical Modeling</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Stem Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Gastroenterology and Hepatology</subject><subj-group><subject>Inflammatory Bowel Disease</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Blood Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>Macrophages</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>Macrophages</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>Macrophages</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>Macrophages</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development</article-title><alt-title alt-title-type="running-head">Mathematical modeling in myeloproliferative cancer</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Andersen</surname><given-names>Morten</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Software</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sajid</surname><given-names>Zamra</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Software</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pedersen</surname><given-names>Rasmus K.</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Software</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gudmand-Hoeyer</surname><given-names>Johanne</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Software</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ellervik</surname><given-names>Christina</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Skov</surname><given-names>Vibe</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kj&#x000e6;r</surname><given-names>Lasse</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pallisgaard</surname><given-names>Niels</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kruse</surname><given-names>Torben A.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Thomassen</surname><given-names>Mads</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Troelsen</surname><given-names>Jesper</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-3936-8032</contrib-id><name><surname>Hasselbalch</surname><given-names>Hans Carl</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Ottesen</surname><given-names>Johnny T.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Software</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Science and Environment, Roskilde University, Roskilde, Denmark</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Laboratory Medicine at Boston Children&#x02019;s Hospital, Boston, Massachusetts, United States of America</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Department of Hematology, Zealand University Hospital, University of Copenhagen, Roskilde, Denmark</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Department of Pathology, Zealand University Hospital, University of Copenhagen, Roskilde, Denmark</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>Department of Clinical Genetics, Odense University Hospital, Odense, Denmark</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Szecsi</surname><given-names>Pal Bela</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Holb&#x000e6;k Hospital, DENMARK</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>C. Ellervik, V. Skov, L. Kj&#x000e6;r, T.A. Kruse, M. Thomassen, M. Andersen, J.T. Ottesen, J. Troelsen, Z. Sajid, R.K. Pedersen and J. Gudmand-Hoeyer have no conflicts of interest to disclose. N. Pallisgaard has the following to disclose: consulting or advisory role for Qiagen and Novartis, participated in speakers bureau (Novartis and Roche), research funding (Incyte and Novartis), holds a patent (patent pending on contamination control of lymphocyte DNA when measuring cell free DNA in liquid biopsies), travel and accommodation (Novartis). H.C. Hasselbalch has the following to disclose: invited speaker and advisory role (Gilead), research funding (Novartis), travel and accommodation (Gilead, PharmaEssentia, Novartis). This does not alter our adherence to PLOS ONE policies on sharing data and materials.</p></fn><corresp id="cor001">* E-mail: <email>hans.hasselbalch@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>8</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>12</volume><issue>8</issue><elocation-id>e0183620</elocation-id><history><date date-type="received"><day>16</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>8</day><month>8</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 Andersen et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Andersen et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0183620.pdf"/><abstract><p>The chronic Philadelphia-negative myeloproliferative neoplasms (MPNs) are acquired stem cell neoplasms which ultimately may transform to acute myelogenous leukemia. Most recently, chronic inflammation has been described as an important factor for the development and progression of MPNs in the biological continuum from early cancer stage to the advanced myelofibrosis stage, the MPNs being described as &#x0201c;A Human Inflammation Model for Cancer Development&#x0201c;. This novel concept has been built upon clinical, experimental, genomic, immunological and not least epidemiological studies. Only a few studies have described the development of MPNs by mathematical models, and none have addressed the role of inflammation for clonal evolution and disease progression. Herein, we aim at using mathematical modelling to substantiate the concept of chronic inflammation as an important trigger and driver of MPNs.The basics of the model describe the proliferation from stem cells to mature cells including mutations of healthy stem cells to become malignant stem cells. We include a simple inflammatory coupling coping with cell death and affecting the basic model beneath. First, we describe the system without feedbacks or regulatory interactions. Next, we introduce inflammatory feedback into the system. Finally, we include other feedbacks and regulatory interactions forming the inflammatory-MPN model.</p><p>Using mathematical modeling, we add further proof to the concept that chronic inflammation may be both a trigger of clonal evolution and an important driving force for MPN disease progression. Our findings support intervention at the earliest stage of cancer development to target the malignant clone and dampen concomitant inflammation.</p></abstract><funding-group><funding-statement>The authors received no specific funding for this work.</funding-statement></funding-group><counts><fig-count count="5"/><table-count count="0"/><page-count count="18"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>The classic chronic Philadelphia-negative myeloproliferative neoplasms (MPNs) include essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF), which are acquired stem cell neoplasms [<xref rid="pone.0183620.ref001" ref-type="bibr">1</xref>]. Most patients live with their MPNs for decades although with a huge morbidity burden due to a high risk of thrombosis with cardiovascular complications and a massive comorbidity burden as well due to an increased propensity to develop autoimmune and chronic inflammatory diseases [<xref rid="pone.0183620.ref002" ref-type="bibr">2</xref>&#x02013;<xref rid="pone.0183620.ref004" ref-type="bibr">4</xref>], including a 40% increased risk of second cancers [<xref rid="pone.0183620.ref005" ref-type="bibr">5</xref>,<xref rid="pone.0183620.ref006" ref-type="bibr">6</xref>]&#x02013;not only after the MPN-diagnosis but also prior to the MPN-diagnosis [<xref rid="pone.0183620.ref007" ref-type="bibr">7</xref>]. Several years prior to the MPN-diagnosis these patients also have an increased risk of cardiovascular, autoimmune and inflammatory diseases [<xref rid="pone.0183620.ref008" ref-type="bibr">8</xref>,<xref rid="pone.0183620.ref009" ref-type="bibr">9</xref>]. Furthermore, the MPNs have an inherent risk of transformation to acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) [<xref rid="pone.0183620.ref010" ref-type="bibr">10</xref>].</p><p>During the last decade major breakthroughs have occurred in the understanding of the pathogenesis of the MPNs, the most important being the identification of the somatic clonal markers&#x02013;JAK2, MPL and CALR [<xref rid="pone.0183620.ref011" ref-type="bibr">11</xref>&#x02013;<xref rid="pone.0183620.ref018" ref-type="bibr">18</xref>]. The findings of several other mutations already at the time of MPN-diagnosis, with the emergence of additional mutations in the advanced transforming stages of MPNs [<xref rid="pone.0183620.ref017" ref-type="bibr">17</xref>,<xref rid="pone.0183620.ref018" ref-type="bibr">18</xref>], all support the concept of a biological continuum from the early cancer stages (ET/PV) to the advanced cancer stages (myelofibrosis or AML) [<xref rid="pone.0183620.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0183620.ref019" ref-type="bibr">19</xref>,<xref rid="pone.0183620.ref020" ref-type="bibr">20</xref>]. Chronic inflammation is the common link between common diseases such as atherosclerosis, the metabolic syndrome, type II diabetes mellitus and cancer, in which the JAK-STAT- signalling and the NF-kB pathways are activated and have major roles in disease progression [<xref rid="pone.0183620.ref021" ref-type="bibr">21</xref>&#x02013;<xref rid="pone.0183620.ref028" ref-type="bibr">28</xref>]. These pathways are activated in MPNs as well. Most recently, the MPNs have been described as &#x0201c;Inflammatory Diseases &#x0201c;[<xref rid="pone.0183620.ref004" ref-type="bibr">4</xref>] and &#x0201c;A Human Inflammation Model For Cancer Development&#x0201d;[<xref rid="pone.0183620.ref029" ref-type="bibr">29</xref>] reflecting chronic inflammation to be a major driving force for clonal evolution and disease progression in MPNs [<xref rid="pone.0183620.ref030" ref-type="bibr">30</xref>&#x02013;<xref rid="pone.0183620.ref039" ref-type="bibr">39</xref>]. This novel concept is built upon a platform, which has combined data from studies in several research fields and disciplines within MPNs&#x02014;clinical [<xref rid="pone.0183620.ref003" ref-type="bibr">3</xref>&#x02013;<xref rid="pone.0183620.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0183620.ref029" ref-type="bibr">29</xref>&#x02013;<xref rid="pone.0183620.ref053" ref-type="bibr">53</xref>], experimental [<xref rid="pone.0183620.ref054" ref-type="bibr">54</xref>&#x02013;<xref rid="pone.0183620.ref063" ref-type="bibr">63</xref>], genomic [<xref rid="pone.0183620.ref064" ref-type="bibr">64</xref>&#x02013;<xref rid="pone.0183620.ref070" ref-type="bibr">70</xref>], immunological [<xref rid="pone.0183620.ref071" ref-type="bibr">71</xref>&#x02013;<xref rid="pone.0183620.ref074" ref-type="bibr">74</xref>] and not least epidemiological studies [<xref rid="pone.0183620.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0183620.ref005" ref-type="bibr">5</xref>&#x02013;<xref rid="pone.0183620.ref007" ref-type="bibr">7</xref>,<xref rid="pone.0183620.ref075" ref-type="bibr">75</xref>&#x02013;<xref rid="pone.0183620.ref077" ref-type="bibr">77</xref>].</p><p>Another research field&#x02014;mathematical modelling of cancer development&#x02014;has not been applied to a similar extent within MPNs until very recently [<xref rid="pone.0183620.ref078" ref-type="bibr">78</xref>,<xref rid="pone.0183620.ref079" ref-type="bibr">79</xref>] and not in the context of investigating the concept of MPNs as &#x0201c;A Human Inflammation Model for Cancer Development&#x0201d;. Mathematical modelling of cancer development has provided new insights regarding cancer initiation and progression [<xref rid="pone.0183620.ref080" ref-type="bibr">80</xref>&#x02013;<xref rid="pone.0183620.ref089" ref-type="bibr">89</xref>]. In this context, mathematical modelling has a huge potential to support or disprove understanding of research data on pathogenetic factors of significance for cancer development but also in regard to providing supportive evidence for a drug to be used in cancer therapy and accordingly a novel tool in evidence-based medicine [<xref rid="pone.0183620.ref090" ref-type="bibr">90</xref>&#x02013;<xref rid="pone.0183620.ref092" ref-type="bibr">92</xref>]. Mathematical modelling of chronic inflammation as the trigger and driver of MPNs has never been investigated. Although the concept of MPNs as &#x0201c;inflammatory diseases&#x0201d; is being increasingly recognized, additional proof of this novel concept by mathematical modelling might be of utmost importance not only for our understanding of the pathogenesis of these neoplasms, but also in regard to diagnosis and treatment. Herein, we for the first time by mathematical modelling add further proof of the concept that MPNs may be both triggered and driven by chronic inflammation. We discuss the perspectives of our findings, which might implicate intervention at the earliest stage of cancer development (ET, PV) to target the malignant clone and dampen concomitant inflammation when the tumor burden is minimal, and accordingly, the outcome of treatment is logically most favorable.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Methods</title><p>The system describes the proliferation from stem cells to mature cells including mutations of healthy stem cells to become malignant stem cells. We include regulatory interactions (e.g. niche growth effects) and inflammation coping with cell death, inflammatory cytokines, and neutrophils. In order to design an inflammatory MPN model, we build on the coupled dynamics of inflammation and cancer progression as depicted in <xref ref-type="fig" rid="pone.0183620.g001">Fig 1</xref>.</p><fig id="pone.0183620.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183620.g001</object-id><label>Fig 1</label><caption><title>The conceptual model.</title><p>Light gray boxes (symbolized x<sub>0</sub>, x<sub>1</sub>, y<sub>0</sub>, and y<sub>1</sub>) illustrate the compartments of the basic model, and the black arrows the rates of the flows between these compartments. Here x<sub>0</sub> denotes the number of HSC, x<sub>1</sub> that of HMS, y<sub>0</sub> that of MPN SC, and y<sub>1</sub> the number of MPN MC. The light blue compartment (symbolized a) contains all dead cells and the light orange compartment (symbolized s) the inflammatory level, i.e. the immune response. Blue arrows from these represent related rates of flows. Red stipulated arrows going from the inflammatory compartment represent effects of the cytokines (or neutrophils when eliminating dead cells) modulating rates of the basic model. Two additional rates (depending on x<sub>0</sub> and y<sub>0</sub>) appearing as red stipulated arrows represent the bone marrow niches symbiosis with the stem cells modulating the self-renewal rates. Note, stem cells leaving their respective compartments enter the corresponding mature cell-pools as multiplied by the progenitor amplification factor (A).</p></caption><graphic xlink:href="pone.0183620.g001"/></fig><sec id="sec003"><title>The model</title><p>Most previous studies attempting to model the role of inflammation and immune deregulation in cancer progression consider solid tumors and couple the T-cell and natural killer (NK) cell dynamics to a logistic growth of a tumor. They mainly describe quite simplified versions of the adaptive immune response without explicitly considering the underlying cancer growth dynamics [<xref rid="pone.0183620.ref093" ref-type="bibr">93</xref>&#x02013;<xref rid="pone.0183620.ref098" ref-type="bibr">98</xref>]. In contrast to all these models, our model is the first which couples the principles underlying actual cell dynamics to a basal inflammatory response. This response is seen for a normal infection, where the amount of dead cells provokes the immune response and stimulates the renewal of stem cells. Despite this complex coupling, the model is kept as simple as possible still allowing the relevant quantities to be described. Thus, the goal is to describe an important coupling between MPN development and the inflammatory response at a quantitatively conceptual level. Hence, the complicated mathematical question of model identifiability and accurate parameter estimation will be addressed elsewhere. Nevertheless, we include some model calibration and validation after presenting the model to justify and demonstrate the strength of the model.</p><p>Basically, our model consists of four pools of cells; the hematopoietic stem cells (HSC), the hematopoietic mature cells (HMC), the MPN-mutated stem cells (MPN SC) and the MPN mature cells (MPN MC). The number of these cells are denoted <italic>x</italic><sub><italic>0</italic></sub>, <italic>x</italic><sub><italic>1</italic></sub>, <italic>y</italic><sub><italic>0</italic></sub>, and <italic>y</italic><sub><italic>1</italic></sub> respectively, where <italic>x</italic> refers to normal hematopoietic cells and <italic>y</italic> to MPN hematopoietic cells, while index <italic>0</italic> refers to stem cells and index <italic>1</italic> to mature cells. A single stem cell (SC) may proliferate in three ways; symmetric self-renewal (having two stem cells as offspring), asymmetric self-renewal (turning into one stem cell and one progenitor cell), and symmetric differentiation (giving rise to two progenitor cells). The progenitor cells cannot be ignored, however, we consider the progenitor cells simply as intermedia multiplication steps describing the way stem cells generate mature cells. In the model, the generations or continuum of progenitor cells will be implicitly accounted for as each stem cell will generate a number of mature cells by an amplification factor, <italic>A (= 2</italic><sup><italic>k</italic></sup> if there are <italic>k</italic> generations of progenitor cells). Feedbacks from or to progenitor cells are ignored or integrated into the other included feedbacks.</p><p>The present focus is on the ensemble of each cell type and not the individual cells; thus the governing laws will be for the pools of cells, in science denoted compartments [<xref rid="pone.0183620.ref099" ref-type="bibr">99</xref>]. Mathematically, the dynamics will be described by non-linear ordinary differential equations respecting conservation laws. The HSC self-renews with rate <italic>r</italic><sub><italic>x</italic></sub> and the malignant MPN SC self-renews with rate <italic>r</italic><sub><italic>y</italic></sub>. Furthermore, HSC may be transformed by cell division by a rate <italic>a</italic><sub><italic>x</italic></sub> whereas the MPN SC does so with a rate <italic>a</italic><sub><italic>y</italic></sub>. The mature cells are multiply generated, i.e. the HMC are generated with a rate <italic>a</italic><sub><italic>x</italic></sub><italic>&#x000b7;A</italic><sub><italic>x</italic></sub> and the MPN MC with a rate <italic>a</italic><sub><italic>y</italic></sub><italic>&#x000b7;A</italic><sub><italic>y</italic></sub>. Finally, all cell types may die; stem cells with a lower rate and mature cells with a higher rate. The turnover (or mortality) rates are <italic>d</italic><sub><italic>x0</italic></sub>, <italic>d</italic><sub><italic>x1</italic></sub>, <italic>d</italic><sub><italic>y0</italic></sub>, and <italic>d</italic><sub><italic>y1</italic></sub> for the HSC, HMC, MPN SC, and MPN MC, respectively. Except for the mutation part and the multiplication factor, this duplicates the structure of the model proposed by Dingli and Michor (they silently used <italic>A = 1)</italic> [<xref rid="pone.0183620.ref092" ref-type="bibr">92</xref>].</p><p>A small probability r<sub>m</sub> describes the mutation of HSC into MPN SC. In that case, r<sub>m</sub> is not the probability of a single mutation but possibly a serial sequence of mutations turning the HSC into a cancer cell capable of self-renewal, by definition an MPN SC, where a mutation is expected to be described by a Poisson process [<xref rid="pone.0183620.ref100" ref-type="bibr">100</xref>]. The probability for one mutation is about 10<sup>&#x02212;7</sup> per year per cell [<xref rid="pone.0183620.ref101" ref-type="bibr">101</xref>]. However, not all mutations are malignant; only mutations which happen on particular locations (i.e. at specific nucleic acids) of the DNA cause MPN relevant mutations. Inflammation increases the risk of mutations, including smoking, exposure to ultraviolet light or certain chemicals [<xref rid="pone.0183620.ref049" ref-type="bibr">49</xref>,<xref rid="pone.0183620.ref050" ref-type="bibr">50</xref>,<xref rid="pone.0183620.ref101" ref-type="bibr">101</xref>&#x02013;<xref rid="pone.0183620.ref104" ref-type="bibr">104</xref>]. It is this small probability which violates a possible deterministic description with a simple mutation rate. Except for the mutation part, the model will be deterministic and continuous. In most of our work, we studied the development right after the first malignant mutation has occurred (denoted the first insult). In these cases, the simulations start with one malignant stem cell. Meanwhile, the number of all other cells are in a healthy steady state with the mutation rate put to zero. The approach is justified by the fact that including a non-zero mutation rate did not affect the outcome of the model.</p><p>The equations are all of the general form,
<disp-formula id="pone.0183620.e001"><alternatives><graphic xlink:href="pone.0183620.e001.jpg" id="pone.0183620.e001g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M1"><mml:mrow><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mtext>Change&#x000a0;in&#x000a0;amount&#x000a0;of&#x000a0;a&#x000a0;</mml:mtext></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mtext>compartment&#x000a0;per&#x000a0;time</mml:mtext></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo>}</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mtext>rate&#x000a0;of&#x000a0;generation&#x000a0;times&#x000a0;</mml:mtext></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mtext>the&#x000a0;generating&#x000a0;source</mml:mtext></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo>}</mml:mo></mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mtext>rate&#x000a0;of&#x000a0;elimination&#x000a0;times&#x000a0;the&#x000a0;amount&#x000a0;&#x000a0;</mml:mtext></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mtext>in&#x000a0;the&#x000a0;compartment&#x000a0;considered</mml:mtext></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></disp-formula>
resulting in specific systems of ordinary differential equations as given in <xref ref-type="supplementary-material" rid="pone.0183620.s001">S1 Appendix</xref>.</p><p>Whenever cells die the debris have to be engulfed by phagocytic cells, e.g. neutrophils and macrophages while a hierarchic cascade of pro- and anti-inflammatory cytokines are released [<xref rid="pone.0183620.ref096" ref-type="bibr">96</xref>&#x02013;<xref rid="pone.0183620.ref098" ref-type="bibr">98</xref>,<xref rid="pone.0183620.ref110" ref-type="bibr">110</xref>]. Following the parsimonious principle, we let the dead cells (a) up-regulate the amount of phagocytic cells (<italic>s</italic>) with rate constant <italic>r</italic><sub><italic>s</italic></sub> per dead cell while they are eliminated with a rate <italic>e</italic><sub><italic>s</italic></sub>. In addition, endotoxins, smoking and other environmental factors may add to the inflammatory response; thus we add such a term (characterized by the lightning symbol in <xref ref-type="fig" rid="pone.0183620.g001">Fig 1</xref>). Since MPNs develop on time-scale years and inflammatory immune processes are fast (on time-scale hours-days), we assume that the amount of phagocytic cells is balanced by the cytokines levels in a fixed ratio. Thus, the cytokine level is proportional to the phagocytic level why the inflammatory compartment (<italic>s</italic>) represents both (up to a possible proportionality constant which may be incorporated into the rate constants). Meanwhile, the amount of dead cells is down-regulated as a second order elimination process, <italic>-e</italic><sub><italic>a</italic></sub><italic>&#x000b7;a&#x000b7;s</italic>, with rate constant <italic>e</italic><sub><italic>a</italic></sub>. Dead cells are produced by <italic>d</italic><sub><italic>0</italic></sub><italic>&#x000b7;x</italic><sub><italic>0</italic></sub><italic>+d</italic><sub><italic>y0</italic></sub><italic>&#x000b7;y</italic><sub><italic>0</italic></sub><italic>+d</italic><sub><italic>x1</italic></sub><italic>&#x000b7;x</italic><sub><italic>1</italic></sub><italic>+d</italic><sub><italic>y1</italic></sub><italic>&#x000b7;y</italic><sub><italic>1</italic></sub> per time denoted the turnover, which is assessed by the plasma concentration of lactic dehydrogenase (LDH). It is well-known that the inflammatory level affects the mutation rate [<xref rid="pone.0183620.ref104" ref-type="bibr">104</xref>] and the self-renewal rates [<xref rid="pone.0183620.ref105" ref-type="bibr">105</xref>]. For simplicity, we take these to be proportional with the inflammatory level (of course saturation may occur) but since the level (a) settles at constant levels so does the inflammatory level (s), which may be thought of as the amount of inflammatory cytokines which have been shown to be increased in patients with MPNs and several in a step-wise manner from controls over the early cancer stages (ET, PV) to the advanced cancer stage&#x02013;myelofibrosis (PMF) (<xref ref-type="supplementary-material" rid="pone.0183620.s001">S1 Appendix</xref>) [<xref rid="pone.0183620.ref040" ref-type="bibr">40</xref>&#x02013;<xref rid="pone.0183620.ref046" ref-type="bibr">46</xref>]. Thus, it turns out that various specific cytokines (IL-1&#x003b2;, IL-1RA, IL-2R, IL-6, IL-8, IL-10, IL-12) and C-reactive protein (CRP)&#x02014;a conventional biomarker of inflammation&#x02014;are linearly correlated with the inflammatory level (s). These cytokines have been chosen for validation of our model since elevated levels of several of these cytokines have been associated with an inferior survival [<xref rid="pone.0183620.ref044" ref-type="bibr">44</xref>]. Likewise, elevated levels of CRP have been shown to be associated with shortened leukemia-free survival in patients with myelofibrosis [<xref rid="pone.0183620.ref042" ref-type="bibr">42</xref>]. Of note, the inflammatory cytokine IL-8 have been reported to be of particular interest in the context of MPN pathogenesis [<xref rid="pone.0183620.ref057" ref-type="bibr">57</xref>&#x02013;<xref rid="pone.0183620.ref060" ref-type="bibr">60</xref>]. These extra pools of cells are depicted in <xref ref-type="fig" rid="pone.0183620.g001">Fig 1</xref> along with the rates governing the dynamics. This establishes the coupled inflammatory-MPN model. The full system of mathematical equations, representing the model is described in Table B in <xref ref-type="supplementary-material" rid="pone.0183620.s001">S1 Appendix</xref> including default parameter values.</p></sec><sec id="sec004"><title>Model calibration, validation, and results</title><p>The model is inspired by Dingli and Michor, and therefore the parameter values are based upon their values [<xref rid="pone.0183620.ref092" ref-type="bibr">92</xref>]. However, we have adjusted them to obtain more appropriate saturation levels in agreement with data (see <xref ref-type="fig" rid="pone.0183620.g002">Fig 2</xref> and the reported values in Table C in <xref ref-type="supplementary-material" rid="pone.0183620.s001">S1 Appendix</xref>). First, the model is calibrated to the situation of no MPN cancer cells (<italic>y</italic><sub>0i</sub> = 0 and <italic>y</italic><sub>1i</sub> = 0). In this situation, we expect a stable steady state such that the number of HSC is approximately 10<sup>4</sup> and that of HMC is approximately 10<sup>10</sup>. These choices are compromises between reported values for the number of HSC [<xref rid="pone.0183620.ref078" ref-type="bibr">78</xref>, <xref rid="pone.0183620.ref086" ref-type="bibr">86</xref>, <xref rid="pone.0183620.ref088" ref-type="bibr">88</xref>, <xref rid="pone.0183620.ref089" ref-type="bibr">89</xref>, <xref rid="pone.0183620.ref092" ref-type="bibr">92</xref>].</p><fig id="pone.0183620.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183620.g002</object-id><label>Fig 2</label><caption><title>Model calibration.</title><p>A) Plateaus to the left show the amount of hematopoietic stem cells <italic>x</italic><sub>0</sub> (upper plateau) and that for MPN stem cells <italic>y</italic><sub>0</sub> (lower plateau) whereas the plateaus to the right show the amount of hematopoietic stem cells <italic>x</italic><sub>0</sub>(lower plateau) and MPN mature cells <italic>y</italic><sub>0</sub> (upper plateau). B) Plateaus to the left show the amount of hematopoietic mature cells <italic>x</italic><sub>1</sub> (upper plateau) and that for MPN mature cells <italic>y</italic><sub>1</sub> (lower plateau) whereas the plateaus to the right show the amount of hematopoietic mature cells <italic>x</italic><sub>1</sub> (lower plateau) and MPN mature cells <italic>y</italic><sub>1</sub> (upper plateau). The yellow and purple boxes show our data used for calibrating (and validating) the model with further details in <xref ref-type="supplementary-material" rid="pone.0183620.s001">S1 Appendix</xref>. Yellow boxes show our &#x0201c;no MPN cancer values&#x0201d;, and purple boxes show our &#x0201c;full blown&#x0201d; MPN values in the advanced myelofibrosis stage. Yellow position marker shows the number of hematopoietic stem cells as used by Dingli &#x00026; Michor [<xref rid="pone.0183620.ref092" ref-type="bibr">92</xref>], and black position markers show the number of cells as used by Gentry et al. [<xref rid="pone.0183620.ref086" ref-type="bibr">86</xref>].</p></caption><graphic xlink:href="pone.0183620.g002"/></fig><p>From the steady state condition we have the number of dead cells to be <inline-formula id="pone.0183620.e002"><alternatives><graphic xlink:href="pone.0183620.e002.jpg" id="pone.0183620.e002g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M2"><mml:mrow><mml:msub><mml:mtext>a</mml:mtext><mml:mtext>x</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>e</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mi>s</mml:mi></mml:mrow></mml:mfrac><mml:mtext>&#x02009;</mml:mtext><mml:mo>&#x02248;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mn>3</mml:mn></mml:msup></mml:mrow></mml:math></alternatives></inline-formula>. We further expect r<sub>x</sub>&#x0003e;d<sub>x0</sub> + a<sub>x</sub> and d<sub>x0</sub> &#x0226a;d<sub>x1</sub>. When allowing for MPN development the healthy state becomes unstable when perturbed by the malignant stem cells. Thus, we expect r<sub>y</sub> &#x0003e;r<sub>x</sub>.</p><p>In the final stage the in silico patient will have vanishing hematopoietic cells and the MPN cells will approach a stable steady state with a higher amount of MPN cells than normal hematopoietic cells in the healthy steady state. This is accomplished by choosing all the c-values equal in order to keep the model as simple as possible and the number of parameters as few as possible. Likewise, the parsimonious principle suggests d<sub>y0</sub> = d<sub>x0</sub>, a<sub>y</sub> = a<sub>x</sub> and A<sub>y</sub> = A<sub>x</sub>.</p><p>The JAK2V617F allele burden has been reported to have median values of 7% (95% CL 2&#x02013;15%; range 1&#x02013;39%), 33% (95% CL 20&#x02013;40%; range 1&#x02013;92%) and 67% (95% CL 52&#x02013;95%; range 37&#x02013;99%) in ET, PV and PMF patients, respectively [<xref rid="pone.0183620.ref019" ref-type="bibr">19</xref>]. It follows that the model output perfectly resamples these dynamic changes in the JAK2V617F mutational load (<xref ref-type="fig" rid="pone.0183620.g003">Fig 3</xref>). Additional details are given in the <xref ref-type="supplementary-material" rid="pone.0183620.s001">S1 Appendix</xref> section.</p><fig id="pone.0183620.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183620.g003</object-id><label>Fig 3</label><caption><p><bold>Left:</bold> Typical development in stem cells (top panel A) and mature cells (bottom panel B). Healthy hematopoietic cells (full blue curves) dominate in the early phase where the number of malignant cells (stipulated red curves) are few. The total number of cells is also shown (dotted green curves). When a stem cell mutates without repairing mechanisms, a slowly increasing exponential growth starts. At a certain stage, the malignant cells become dominant, and the healthy hematopoietic cells begin to show a visible decline. Finally, the composition between the cell types results in a takeover by the malignant cells, leading to an exponential decline in hematopoietic cells and ultimately their extinction. The development is driven by an approximately exponential increase in the MPN stem cells, and the development is closely followed by the mature MPN cells. <bold>Right:</bold> B)The corresponding allele burden (7%, 33% and 67% corresponding to ET, PV, and PMF, respectively) defined as the ratio of MPN mature cells to the total number of mature cells.</p></caption><graphic xlink:href="pone.0183620.g003"/></fig><p>All these attempts in calibrating the model may simultaneously be considered as validation since they performed successfully. However, the model may be validated further by predicting affected cytokine levels from the inflammatory level. As indicators of the inflammatory level, we refer to those cytokines, which are considered most important in the context of MPNs: IL-1&#x003b2;, IL-1RA, IL-2R, IL-6, IL-8, IL-10, IL-12 and the inflammation biomarker CRP which all turned out to be linearly correlated with the inflammatory level (s).</p><p>For the specific cytokines (<italic>C</italic><sub><italic>i</italic></sub>) tabulated in the <xref ref-type="supplementary-material" rid="pone.0183620.s001">S1 Appendix</xref>, we have &#x02018;Normal&#x02019;, &#x02018;PV&#x02019;, and &#x02018;PMF&#x02019; median values (<italic>m</italic><sub><italic>ij</italic></sub>, where index <italic>i</italic> specifies the cytokine and index <italic>j</italic> refers to &#x02018;Normal&#x02019;, &#x02018;PV&#x02019; and &#x02018;PMF&#x02019; states) for each. Then we find <italic>k</italic><sub><italic>i</italic>1</sub> and <italic>k</italic><sub><italic>i</italic>2</sub> such that <italic>m</italic><sub><italic>ij</italic></sub> = <italic>k</italic><sub>i1</sub>
<italic>s</italic><sub>j</sub>+<italic>k</italic><sub>i2</sub> where <italic>s</italic><sub><italic>j</italic></sub> is the value of s at year <italic>t</italic><sub><italic>j</italic></sub>. Similarly, LDH values were demonstrated to be correlated and compared to the total rate of dying cells <italic>DI</italic> = <italic>dx</italic><sub>0</sub><italic>x</italic><sub>0</sub> + <italic>dx</italic><sub>1</sub><italic>x</italic><sub>1</sub> + <italic>dy</italic><sub>0</sub><italic>y</italic><sub>0</sub> + <italic>dy</italic><sub>1</sub><italic>y</italic><sub>1</sub>. The results are summarized in <xref ref-type="fig" rid="pone.0183620.g004">Fig 4</xref> which shows that the model predicts data very well. Only IL-6 seems to be less well predicted.</p><fig id="pone.0183620.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183620.g004</object-id><label>Fig 4</label><caption><title>Model validation.</title><p>Cytokines A) IL-1&#x003b2;, B) IL-1RA, C) IL-2R, D) IL-6, E) IL-8, F) IL-10, G) IL-12 and H) C-reactive proteins (CRP) are approximatively linearly correlated with the inflammatory level s. For the specific cytokines, we have from left to right &#x02018;Normal&#x02019;, &#x02018;PV&#x02019;, and &#x02018;PMF&#x02019; median values (yellow columns) for comparison based on the predicted inflammatory level s (full blue curve) as a function of time after the first insult. I) Similarly, LDH is correlated with and compared to the total rate of dying cells <italic>DI</italic> = <italic>dx</italic><sub>0</sub><italic>x</italic><sub>0</sub> + <italic>dx</italic><sub>1</sub><italic>x</italic><sub>1</sub> + <italic>dy</italic><sub>0</sub><italic>y</italic><sub>0</sub> + <italic>dy</italic><sub>1</sub><italic>y</italic><sub>1</sub>.</p></caption><graphic xlink:href="pone.0183620.g004"/></fig><p>Disallowing potential mutations and having no MPN-stem cells initially forces the model system into a steady state where solutions are all constant after a possible initial transient event. Introducing a mutation probability introduces a fatal malignant state; the higher the mutation probability is the faster the malignant state develops. A typical scenario is shown in <xref ref-type="fig" rid="pone.0183620.g003">Fig 3A</xref> along with a curve of the allele burden development (<xref ref-type="fig" rid="pone.0183620.g003">Fig 3B</xref>). The Figure depicts both modeling of the development of MPN from normal HSC and the early MPN diseases stages (ET/PV) to the advanced myelofibrosis stage.</p><p>Having a continuous mutation rate, it will take 24 years for the disease to develop to an allele burden of 7% (e.g. ET) and after additional four years the allele burden reaches 33% (e.g. transformation of ET to PV) to become 67% (e.g. transformation of PV to post-PV myelofibrosis) at year 36 after the first stem cell mutation. Disallowing mutations in the model and initially including a single malignant stem cell and no malignant mature cells shifts the allele burden curve by one year to the left on the time axis.</p><p>Thus, the mutation of an HSC to MPN SC triggers the disease. Once an MPN stem cell is established the disease can progress without further mutations.</p><p>The baseline inflammatory load (stimulus) is arbitrarily set to 7 pg/ml per day during normal circumstances. It is an exogenous stimulation of the immune system, which leads to an inflammatory level of 3.61 pg/ml, increasing to 3.66 pg/ml in MPNs. This corresponds to a baseline of 700 dead cells (in the hematopoietic steady state) before MPN develops remarkably. A doubling of the baseline inflammatory level is directly affecting the inflammation load (cytokine level) and thereby affecting the rest of the system as dictated by the model equations. In <xref ref-type="fig" rid="pone.0183620.g005">Fig 5</xref> is depicted that shortening the exposure time of inflammation load is associated with deceleration of disease progression.</p><fig id="pone.0183620.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183620.g005</object-id><label>Fig 5</label><caption><title>Investigation of increased inflammatory load at various onsets and durations.</title><p>Blue curve is default parameters corresponding to <xref ref-type="fig" rid="pone.0183620.g003">Fig 3</xref>, red dotted is a doubling of inflammatory load, full red curve is a doubling of inflammatory load in year 0&#x02013;20, then back to default level, black dotted curve is inflammatory doubling from year 10, the full black is inflammatory doubling year 10&#x02013;30. <bold>Upper:</bold> Increasing inflammatory load has a boosting effect on MPN MC (A) as well as on HMC (B). <bold>Lower:</bold> Displaying the results in terms of the clinically available quantity, total blood cell count, also shows a boosted effect with increasing inflammatory load (C). The allele burden of JAK2 mutated blood cells similarly shows that increased inflammation increases disease development (D). There is a clear effect of MPN promotion with increasing inflammatory load, earlier onset, and exposure time. Lowering inflammatory load makes disease progression less rapid. Maintaining a doubling (red dotted curve) shifts the allele burden curve to the left by two years. Shortening the exposure time of inflammatory load weakens the disease progression. The inflammation has a fast impact on the total number of blood cells, which typically changes by 25% within the first year after doubling or reducing the inflammatory load by 50%.</p></caption><graphic xlink:href="pone.0183620.g005"/></fig></sec></sec><sec sec-type="conclusions" id="sec005"><title>Discussion</title><p>Chronic inflammation is characterized by persistently activated immune cells, DNA damage, tissue destruction, remodeling and fibrosis [<xref rid="pone.0183620.ref106" ref-type="bibr">106</xref>]. In patients with MPNs, these processes are exemplified by the advanced myelofibrosis stage [<xref rid="pone.0183620.ref004" ref-type="bibr">4</xref>, <xref rid="pone.0183620.ref029" ref-type="bibr">29</xref>], which accordingly might be considered to develop as the consequence of chronic inflammation in the bone marrow&#x02013;&#x0201c;the inflamed bone marrow&#x0201d; and &#x0201c;the wound that won&#x02019;t heal&#x0201d; [<xref rid="pone.0183620.ref004" ref-type="bibr">4</xref>, <xref rid="pone.0183620.ref029" ref-type="bibr">29</xref>,<xref rid="pone.0183620.ref107" ref-type="bibr">107</xref>,<xref rid="pone.0183620.ref108" ref-type="bibr">108</xref>]. Herein, we for the first time use mathematical modelling to substantiate the concept that MPN progression is facilitated by chronic inflammation and that ET and PV are linked through increasing JAK2V617F allele burden [<xref rid="pone.0183620.ref019" ref-type="bibr">19</xref>] which is destined to happen as time increases without interference. Importantly, we were able to create the inflammation-MPN model based upon current knowledge on the interactions between inflammatory cytokines, hematopoietic stem cells and progenitors, and the bone marrow microenvironment [<xref rid="pone.0183620.ref031" ref-type="bibr">31</xref>&#x02013;<xref rid="pone.0183620.ref033" ref-type="bibr">33</xref>,<xref rid="pone.0183620.ref035" ref-type="bibr">35</xref>&#x02013;<xref rid="pone.0183620.ref037" ref-type="bibr">37</xref>,<xref rid="pone.0183620.ref105" ref-type="bibr">105</xref>]. By mathematical modelling of all these interactions, our integrated inflammation-MPN model was created. The model was validated from current data on circulating inflammatory cytokines in MPNs [<xref rid="pone.0183620.ref040" ref-type="bibr">40</xref>,<xref rid="pone.0183620.ref044" ref-type="bibr">44</xref>&#x02013;<xref rid="pone.0183620.ref046" ref-type="bibr">46</xref>], thereby substantiating inflammation to be a highly potent stimulus for clonal evolution and cancer progression in MPNs. In the context that elevated CRP levels have been shown to be associated with shortened leukemia-free survival in myelofibrosis [<xref rid="pone.0183620.ref042" ref-type="bibr">42</xref>], it is of interest that our model was excellently validated by data on CRP levels in the different MPN disease stages as well.</p><p>Mathematical modelling has been used to describe the impact of chronic inflammation and immune deregulation in aging [<xref rid="pone.0183620.ref109" ref-type="bibr">109</xref>] and several diseases, including type 1 diabetes mellitus [<xref rid="pone.0183620.ref110" ref-type="bibr">110</xref>], rheumatoid arthritis [<xref rid="pone.0183620.ref096" ref-type="bibr">96</xref>] and colitis-associated colon cancer [<xref rid="pone.0183620.ref111" ref-type="bibr">111</xref>]. Based upon the known association between respiratory infections and chronic inflammation, Herald described a general model of inflammation [<xref rid="pone.0183620.ref097" ref-type="bibr">97</xref>]. In this model, a system of nonlinear ordinary differential equations was used to describe interactions between macrophages, inflammatory and anti-inflammatory cytokines and bacteria. Though initiated by bacteria as the stimulus to trigger chronic inflammation, their study focused on chronic inflammation in the absence of pathogens as well [<xref rid="pone.0183620.ref097" ref-type="bibr">97</xref>]. Of note, even small changes in parameters of importance for inflammatory cytokine production and macrophage sensitivity to cytokines resulted in dramatically different model behaviors [<xref rid="pone.0183620.ref097" ref-type="bibr">97</xref>]. According to this model chronic inflammation is not triggered when the immune system is functioning properly. However, in patients with a dysfunction of the immune system positive feedback of the inflammatory cytokine network is prone to induce chronic inflammation. Furthermore, if the macrophage population is more sensitive to inflammatory cytokines small perturbations initiated by the inflammation stimulus will also lead to chronic inflammation [<xref rid="pone.0183620.ref097" ref-type="bibr">97</xref>]. In this context, it is intriguing to consider if the inherited genetic predisposition to acquire the JAK2V617F-mutation due to the haplotype 46/1 [<xref rid="pone.0183620.ref112" ref-type="bibr">112</xref>&#x02013;<xref rid="pone.0183620.ref117" ref-type="bibr">117</xref>], which also confers an increased risk of (other) inflammatory diseases (e.g. Crohns&#x02019; disease) [<xref rid="pone.0183620.ref118" ref-type="bibr">118</xref>,<xref rid="pone.0183620.ref119" ref-type="bibr">119</xref>] and /or acquired genetic instability due to sustained chronic inflammation (chronic inflammatory diseases or toxin exposure (e.g. smoking) might further increase the risk of developing MPN&#x02014;a hypothesis originally proposed by Hermouet et al [<xref rid="pone.0183620.ref033" ref-type="bibr">33</xref>,<xref rid="pone.0183620.ref035" ref-type="bibr">35</xref>]. Importantly, the hypersensitivity of clonal MPN-cells to exogenous and endogenous growth factors and inflammatory cytokines might also more easily lead to a chronic inflammatory state&#x02013;similar to the increased sensitivity of the macrophage population leading to chronic inflammation in the Herald model and also implemented in the Hermouet model, implying an enhanced myelomonocytic response to cytokine stimulation [<xref rid="pone.0183620.ref033" ref-type="bibr">33</xref>,<xref rid="pone.0183620.ref035" ref-type="bibr">35</xref>].</p><p>In the Herald model and the model described by Nielsen et al in regard to type 1 diabetes mellitus, the macrophages constituted an important compartment [<xref rid="pone.0183620.ref097" ref-type="bibr">97</xref>,<xref rid="pone.0183620.ref110" ref-type="bibr">110</xref>]. The monocyte-macrophage cell lineage is of major importance in the context of inflammation and cancer development. In our MPN-inflammation model bone marrow macrophages are also of utmost importance&#x02014;both in regard to release of inflammatory cytokines, but also in regard to the development of myelofibrosis. Thus, in MPNs the monocyte-macrophage cell&#x02014;together with the megakaryocyte (MK) cell lineage&#x02014;are considered to be responsible for the development of myelofibrosis by the release of a number of growth factors and inflammatory cytokines that stimulate fibroblast proliferation [<xref rid="pone.0183620.ref036" ref-type="bibr">36</xref>,<xref rid="pone.0183620.ref120" ref-type="bibr">120</xref>,<xref rid="pone.0183620.ref121" ref-type="bibr">121</xref>]. The &#x0201c;Herald Model&#x0201d; is in several aspects equivalent to our model when considering substituting &#x0201c;bacteria&#x0201d;in the &#x0201c;Herald Model&#x0201d; by any noxious inflammatory stimulus. In fact, we implement yet another cell lineage&#x02014;the MKs&#x02014;as the source of a continuous release of products that stimulate the vicious inflammation circle, implying ultimately the development of cancer&#x02014;the MPNs. As previously outlined, our mathematical modelling of the concept of chronic inflammation in MPNs is also supported by the elegant model described by Hermouet and co-workers [<xref rid="pone.0183620.ref033" ref-type="bibr">33</xref>,<xref rid="pone.0183620.ref035" ref-type="bibr">35</xref>], in which the <italic>JAK2</italic> 46/1 haplotype was proposed as a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasms, and impaired defense against infection [<xref rid="pone.0183620.ref033" ref-type="bibr">33</xref>]. Indeed, the Hermouet model for chronic inflammation [<xref rid="pone.0183620.ref033" ref-type="bibr">33</xref>,<xref rid="pone.0183620.ref035" ref-type="bibr">35</xref>] fits exceedingly well with the Herald model of general inflammation [<xref rid="pone.0183620.ref097" ref-type="bibr">97</xref>] and our mathematical modelling of MPNs as &#x0201c;A Human Inflammation Mode for Cancer Development [<xref rid="pone.0183620.ref029" ref-type="bibr">29</xref>&#x02013;<xref rid="pone.0183620.ref032" ref-type="bibr">32</xref>]. In this regard, chronic inflammation and immune deregulation in MPNs might act as a trigger for later development of AML and MDS in line with the known association of inflammatory signaling and cancer [<xref rid="pone.0183620.ref024" ref-type="bibr">24</xref>&#x02013;<xref rid="pone.0183620.ref027" ref-type="bibr">27</xref>]. The above models are additionally supported by the hypothetical model by Takizawa et al. (2010) [<xref rid="pone.0183620.ref122" ref-type="bibr">122</xref>], describing how chronic inflammatory processes might impinge on hematopoiesis, potentially fostering hematopoietic stem cell diseases, including MPNs. By inducing high proliferation of most HSCs, chronic inflammation might give rise to both exhaustion of the HSC pool and an even greater risk to accumulate genetic alterations in HSCs. Furthermore, by inflammatory stimuli from the bone marrow microenvironment these genetically altered HSCs might be rescued or &#x0201c;cancer cell niche&#x0201d; for later development of a hematological cancer [<xref rid="pone.0183620.ref122" ref-type="bibr">122</xref>].</p><p>The perspectives of our study are several. In the context that myelomonocytic cells (granulocytes, macrophages, monocytes) and MKs are all deeply involved in cancer development and progression [<xref rid="pone.0183620.ref123" ref-type="bibr">123</xref>,<xref rid="pone.0183620.ref124" ref-type="bibr">124</xref>], chronic inflammation is associated with premature atherosclerosis (atherothrombosis) [<xref rid="pone.0183620.ref021" ref-type="bibr">21</xref>&#x02013;<xref rid="pone.0183620.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0183620.ref029" ref-type="bibr">29</xref>,<xref rid="pone.0183620.ref030" ref-type="bibr">30</xref>], in which both platelets and monocytes are highly important (monocytes a link between atherosclerosis and cancer [<xref rid="pone.0183620.ref028" ref-type="bibr">28</xref>]) and platelets are intimately involved in the metastatic process in cancer [<xref rid="pone.0183620.ref124" ref-type="bibr">124</xref>]&#x02014;and likely in MPNs as well [<xref rid="pone.0183620.ref125" ref-type="bibr">125</xref>]&#x02014;the avenue is opened for studying all these aspects by using mathematical modelling of current knowledge of the impact of chronic inflammation and immune deregulation in patients with MPNs. Ultimately, mathematical modelling may also be able to substantiate which agents to be used in MPNs in order to induce &#x0201c;minimal residual disease&#x0201d;[<xref rid="pone.0183620.ref125" ref-type="bibr">125</xref>&#x02013;<xref rid="pone.0183620.ref129" ref-type="bibr">129</xref>] and the importance of early intervention with agents that directly target both the malignant clone (interferon-alpha2) [<xref rid="pone.0183620.ref126" ref-type="bibr">126</xref>&#x02013;<xref rid="pone.0183620.ref129" ref-type="bibr">129</xref>] and the inflammatory process (JAK1-2 inhibition with e.g. ruxolitinib) [<xref rid="pone.0183620.ref130" ref-type="bibr">130</xref>].</p><p>In conclusion, we have for the first time applied mathematical modelling as a tool to deliver the proof of concept that chronic inflammation is closely linked to the development of the MPNs&#x02014;myeloproliferative cancers which today are considered to be &#x0201c;chronic inflammatory diseases&#x0201d;, in which chronic inflammation may be a driving force for clonal expansion and ultimately the development of AML [<xref rid="pone.0183620.ref004" ref-type="bibr">4</xref>, <xref rid="pone.0183620.ref029" ref-type="bibr">29</xref>&#x02013;<xref rid="pone.0183620.ref032" ref-type="bibr">32</xref>,<xref rid="pone.0183620.ref039" ref-type="bibr">39</xref>]. Studies are ongoing to elucidate the above perspectives by mathematical modelling. In this regard, mathematical modelling of resolution of inflammation may be highly important [<xref rid="pone.0183620.ref098" ref-type="bibr">98</xref>] and useful to support the decision-making which agents to use in the future for patients with MPNs in order to induce minimal residual disease and hopefully cure.</p></sec><sec sec-type="supplementary-material" id="sec006"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0183620.s001"><label>S1 Appendix</label><caption><p>(DOCX)</p></caption><media xlink:href="pone.0183620.s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0183620.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Campbell</surname><given-names>PJ</given-names></name>, <name><surname>Green</surname><given-names>AR</given-names></name>. <article-title>The myeloproliferative disorders</article-title>. <source>N Engl J Med</source>. <year>2006</year>; <volume>355</volume> (<issue>23</issue>): <fpage>2452</fpage>&#x02013;<lpage>2466</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMra063728">10.1056/NEJMra063728</ext-link></comment>
<pub-id pub-id-type="pmid">17151367</pub-id></mixed-citation></ref><ref id="pone.0183620.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Marchioli</surname><given-names>R</given-names></name>, <name><surname>Finazzi</surname><given-names>G</given-names></name>, <name><surname>Landolfi</surname><given-names>R</given-names></name>, <name><surname>Kutti</surname><given-names>J</given-names></name>, <name><surname>Gisslinger</surname><given-names>H</given-names></name>, <name><surname>Patrono</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Vascular and neoplastic risk in a large cohort of patients with polycythemia vera</article-title>. <source>J Clin Oncol</source>. <year>2005</year>; <volume>23</volume>: <fpage>2224</fpage>&#x02013;<lpage>2232</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1200/JCO.2005.07.062">10.1200/JCO.2005.07.062</ext-link></comment>
<pub-id pub-id-type="pmid">15710945</pub-id></mixed-citation></ref><ref id="pone.0183620.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Kristinsson</surname><given-names>SY</given-names></name>, <name><surname>Landgren</surname><given-names>O</given-names></name>, <name><surname>Samuelsson</surname><given-names>J</given-names></name>
<name><surname>Bj&#x000f6;rkholm</surname><given-names>M</given-names></name>, <name><surname>Goldin</surname><given-names>LR</given-names></name>. <article-title>Autoimmunity and the risk of myeloproliferative neoplasms</article-title>. <source>Haematologica</source>. <year>2010</year>; <volume>95</volume>(<issue>7</issue>): <fpage>1216</fpage>&#x02013;<lpage>1220</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3324/haematol.2009.020412">10.3324/haematol.2009.020412</ext-link></comment>
<pub-id pub-id-type="pmid">20053870</pub-id></mixed-citation></ref><ref id="pone.0183620.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Hasselbalch</surname><given-names>HC</given-names></name>, <name><surname>Bj&#x000f8;rn</surname><given-names>ME</given-names></name>. <article-title>MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives</article-title>. <source>Mediators Inflamm</source>. <year>2015</year>: <fpage>102476</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1155/2015/102476">10.1155/2015/102476</ext-link></comment>
<pub-id pub-id-type="pmid">26604428</pub-id></mixed-citation></ref><ref id="pone.0183620.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Frederiksen</surname><given-names>H</given-names></name>, <name><surname>Farkas</surname><given-names>DK</given-names></name>, <name><surname>Christiansen</surname><given-names>CF</given-names></name>
<name><surname>Hasselbalch</surname><given-names>HC</given-names></name>, <name><surname>S&#x000f8;rensen</surname><given-names>HT</given-names></name>. <article-title>Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study</article-title>. <source>Blood</source>. <year>2011</year>; <volume>118</volume>(<issue>25</issue>): <fpage>6515</fpage>&#x02013;<lpage>6520</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2011-04-348755">10.1182/blood-2011-04-348755</ext-link></comment>
<pub-id pub-id-type="pmid">22039256</pub-id></mixed-citation></ref><ref id="pone.0183620.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Frederiksen</surname><given-names>H</given-names></name>, <name><surname>Farkas</surname><given-names>DK</given-names></name>, <name><surname>Christiansen</surname><given-names>CF</given-names></name>, <name><surname>Larsen</surname><given-names>TS</given-names></name>, <name><surname>Hasselbalch</surname><given-names>HC</given-names></name>, <name><surname>Stentoft</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Survival of patients with chronic myeloproliferative neoplasms and new primary cancers: a population-based cohort study</article-title>. <source>Lancet Haematol</source>. <year>2015</year>; <volume>2</volume>(<issue>7</issue>): <fpage>e289</fpage>&#x02013;<lpage>296</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S2352-3026(15)00092-7">10.1016/S2352-3026(15)00092-7</ext-link></comment>
<pub-id pub-id-type="pmid">26688384</pub-id></mixed-citation></ref><ref id="pone.0183620.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Pettersson</surname><given-names>H</given-names></name>, <name><surname>Knutsen</surname><given-names>H</given-names></name>, <name><surname>Holmberg</surname><given-names>E</given-names></name>, <name><surname>Andreasson</surname><given-names>B</given-names></name>. <article-title>Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis</article-title>. <source>Eur J Haematol</source>. <year>2015</year>; <volume>94</volume>(<issue>2</issue>): <fpage>152</fpage>&#x02013;<lpage>156</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/ejh.12410">10.1111/ejh.12410</ext-link></comment>
<pub-id pub-id-type="pmid">25039361</pub-id></mixed-citation></ref><ref id="pone.0183620.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Enblom</surname><given-names>A</given-names></name>, <name><surname>Lindskog</surname><given-names>E</given-names></name>, <name><surname>Hasselbalch</surname><given-names>HC</given-names></name>, <name><surname>Hersby</surname><given-names>D</given-names></name>, <name><surname>Bak</surname><given-names>M</given-names></name>, <name><surname>Tetu</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms</article-title>. <source>Eur J Intern Med</source>. <year>2015</year>; <volume>26</volume>(<issue>5</issue>): <fpage>344</fpage>&#x02013;<lpage>347</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ejim.2015.03.009">10.1016/j.ejim.2015.03.009</ext-link></comment>
<pub-id pub-id-type="pmid">25863408</pub-id></mixed-citation></ref><ref id="pone.0183620.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>S&#x000f8;rensen</surname><given-names>AL</given-names></name>, <name><surname>Hasselbalch</surname><given-names>HC</given-names></name>. <article-title>Antecedent cardiovascular disease and autoimmunity in Philadelphia-negative chronic myeloproliferative neoplasms</article-title>. <source>Leuk Res</source>. <year>2016</year>; <volume>41</volume>: <fpage>27</fpage>&#x02013;<lpage>35</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.leukres.2015.11.017">10.1016/j.leukres.2015.11.017</ext-link></comment>
<pub-id pub-id-type="pmid">26718091</pub-id></mixed-citation></ref><ref id="pone.0183620.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Bjorkholm</surname><given-names>M</given-names></name>, <name><surname>Derolf</surname><given-names>AR</given-names></name>, <name><surname>Hultcrantz</surname><given-names>M</given-names></name>, <name><surname>Kristinsson</surname><given-names>SY</given-names></name>, <name><surname>Ekstrand</surname><given-names>C</given-names></name>, <name><surname>Goldin</surname><given-names>LR</given-names></name>. <article-title>Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms</article-title>. <source>J Clin Oncol</source>. <year>2011</year>: <volume>29</volume>(<issue>17</issue>): <fpage>2410</fpage>&#x02013;<lpage>2415</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1200/JCO.2011.34.7542">10.1200/JCO.2011.34.7542</ext-link></comment>
<pub-id pub-id-type="pmid">21537037</pub-id></mixed-citation></ref><ref id="pone.0183620.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>James</surname><given-names>C</given-names></name>, <name><surname>Ugo</surname><given-names>V</given-names></name>, <name><surname>Le Cou&#x000e9;dic</surname><given-names>J-P</given-names></name>, <name><surname>Staerk</surname><given-names>J</given-names></name>, <name><surname>Delhommeau</surname><given-names>F</given-names></name>, <name><surname>Lacout</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera</article-title>. <source>Nature</source>. <year>2005</year>; <volume>434</volume>: <fpage>1144</fpage>&#x02013;<lpage>1148</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature03546">10.1038/nature03546</ext-link></comment>
<pub-id pub-id-type="pmid">15793561</pub-id></mixed-citation></ref><ref id="pone.0183620.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Kralovics</surname><given-names>R</given-names></name>, <name><surname>Passamonti</surname><given-names>F</given-names></name>, <name><surname>Buser</surname><given-names>AS</given-names></name>, <name><surname>Teo</surname><given-names>SS</given-names></name>, <name><surname>Tiedt</surname><given-names>R</given-names></name>, <name><surname>Passweg</surname><given-names>JR</given-names></name>, <etal>et al</etal>
<article-title>A gain-of-function mutation of JAK2 in myeloproliferative disorders</article-title>. <source>N Engl J Med</source>. <year>2005</year>; <volume>352</volume>(<issue>17</issue>): <fpage>1779</fpage>&#x02013;<lpage>1790</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa051113">10.1056/NEJMoa051113</ext-link></comment>
<pub-id pub-id-type="pmid">15858187</pub-id></mixed-citation></ref><ref id="pone.0183620.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Baxter</surname><given-names>EJ</given-names></name>, <name><surname>Scott</surname><given-names>LM</given-names></name>, <name><surname>Campbell</surname><given-names>PJ</given-names></name>, <name><surname>East</surname><given-names>C</given-names></name>, <name><surname>Fourouclas</surname><given-names>N</given-names></name>, <name><surname>Swanton</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders</article-title>. <source>Lancet</source>. <year>2005</year>; <volume>365</volume>(<issue>9464</issue>): <fpage>1054</fpage>&#x02013;<lpage>1061</lpage>.<pub-id pub-id-type="pmid">15781101</pub-id></mixed-citation></ref><ref id="pone.0183620.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Levine</surname><given-names>RL</given-names></name>, <name><surname>Wadleigh</surname><given-names>M</given-names></name>, <name><surname>Cools</surname><given-names>J</given-names></name>, <name><surname>Ebert</surname><given-names>BL</given-names></name>, <name><surname>Wernig</surname><given-names>G</given-names></name>, <name><surname>Huntly</surname><given-names>BJ</given-names></name>, <etal>et al</etal>
<article-title>Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis</article-title>. <source>Cancer Cell</source>. <year>2005</year>; <volume>7</volume>(<issue>4</issue>): <fpage>387</fpage>&#x02013;<lpage>397</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ccr.2005.03.023">10.1016/j.ccr.2005.03.023</ext-link></comment>
<pub-id pub-id-type="pmid">15837627</pub-id></mixed-citation></ref><ref id="pone.0183620.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Klampfl</surname><given-names>T</given-names></name>, <name><surname>Gisslinger</surname><given-names>H</given-names></name>, <name><surname>Harutyunyan</surname><given-names>AS</given-names></name>, <etal>et al</etal>
<article-title>Somatic mutations of calreticulin in myeloproliferative neoplasms</article-title>. <source>N Engl J Med</source>. <year>2013</year>; <volume>369</volume>(<issue>25</issue>): <fpage>2379</fpage>&#x02013;<lpage>2390</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa1311347">10.1056/NEJMoa1311347</ext-link></comment>
<pub-id pub-id-type="pmid">24325356</pub-id></mixed-citation></ref><ref id="pone.0183620.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Nangalia</surname><given-names>J</given-names></name>, <name><surname>Massie</surname><given-names>CE</given-names></name>, <name><surname>Baxter</surname><given-names>EJ</given-names></name>, <name><surname>Nivarthi</surname><given-names>H</given-names></name>, <name><surname>Rumi</surname><given-names>E</given-names></name>, <name><surname>Milosevic</surname><given-names>JD</given-names></name>, <etal>et al</etal>
<article-title>Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2</article-title>. <source>N Engl J Med</source>. <year>2013</year>; <volume>369</volume>(<issue>25</issue>): <fpage>2391</fpage>&#x02013;<lpage>2405</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa1312542">10.1056/NEJMoa1312542</ext-link></comment>
<pub-id pub-id-type="pmid">24325359</pub-id></mixed-citation></ref><ref id="pone.0183620.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Cazzola</surname><given-names>M</given-names></name>, <name><surname>Kralovics</surname><given-names>R</given-names></name>. <article-title>From Janus kinase 2 to calreticulin: The clinically relevant genomic landscape of myeloproliferative neoplasms</article-title>. <source>Blood</source>. <year>2014</year>; <volume>123</volume>(<issue>24</issue>): <fpage>3714</fpage>&#x02013;<lpage>3719</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2014-03-530865">10.1182/blood-2014-03-530865</ext-link></comment>
<pub-id pub-id-type="pmid">24786775</pub-id></mixed-citation></ref><ref id="pone.0183620.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Lundberg</surname><given-names>P</given-names></name>, <name><surname>Karow</surname><given-names>A</given-names></name>, <name><surname>Nienhold</surname><given-names>R</given-names></name>, <name><surname>Looser</surname><given-names>R</given-names></name>, <name><surname>Hao-Shen</surname><given-names>H</given-names></name>, <name><surname>Nissen</surname><given-names>I</given-names></name>, <etal>et al</etal>
<article-title>Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms</article-title>. <source>Blood</source>. <year>2014</year>; <volume>123</volume>(<issue>14</issue>): <fpage>2220</fpage>&#x02013;<lpage>2228</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2013-11-537167">10.1182/blood-2013-11-537167</ext-link></comment>
<pub-id pub-id-type="pmid">24478400</pub-id></mixed-citation></ref><ref id="pone.0183620.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Larsen</surname><given-names>TS</given-names></name>, <name><surname>Pallisgaard</surname><given-names>N</given-names></name>, <name><surname>M&#x000f8;ller</surname><given-names>MB</given-names></name>, <name><surname>Hasselbalch</surname><given-names>HC</given-names></name>. <article-title>The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis&#x02014;impact on disease phenotype</article-title>. <source>Eur J Haematol</source>. <year>2007</year>; <volume>79</volume>(<issue>6</issue>); <fpage>508</fpage>&#x02013;<lpage>515</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1600-0609.2007.00960.x">10.1111/j.1600-0609.2007.00960.x</ext-link></comment>
<pub-id pub-id-type="pmid">17961178</pub-id></mixed-citation></ref><ref id="pone.0183620.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Barosi</surname><given-names>G</given-names></name>, <name><surname>Rosti</surname><given-names>V</given-names></name>, <name><surname>Bonetti</surname><given-names>E</given-names></name>, <name><surname>Campanelli</surname><given-names>R</given-names></name>, <name><surname>Carolei</surname><given-names>A</given-names></name>, <name><surname>Catarsi</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Evidence that Prefibrotic Myelofibrosis Is Aligned along a Clinical and Biological Continuum Featuring Primary Myelofibrosis</article-title>. <source>PLoS One</source>. <year>2012</year>; <volume>7</volume>(<issue>4</issue>): <fpage>e35631</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0035631">10.1371/journal.pone.0035631</ext-link></comment>
<pub-id pub-id-type="pmid">22536419</pub-id></mixed-citation></ref><ref id="pone.0183620.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Danesh</surname><given-names>J</given-names></name>, <name><surname>Whincup</surname><given-names>P</given-names></name>, <name><surname>Walker</surname><given-names>M</given-names></name>, <name><surname>Lennon</surname><given-names>L</given-names></name>, <name><surname>Thomson</surname><given-names>A</given-names></name>, <name><surname>Appleby</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses</article-title>. <source>BMJ</source>. <year>2000</year>; <volume>321</volume>: <fpage>199</fpage>&#x02013;<lpage>204</lpage>. <pub-id pub-id-type="pmid">10903648</pub-id></mixed-citation></ref><ref id="pone.0183620.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Ridker</surname><given-names>PM</given-names></name>, <name><surname>Cushman</surname><given-names>M</given-names></name>, <name><surname>Stampfer</surname><given-names>MJ</given-names></name>, <name><surname>Tracy</surname><given-names>RP</given-names></name>, <name><surname>Hennekens</surname><given-names>CH</given-names></name>. <article-title>Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease</article-title>. <source>Circulation</source>. <year>1998</year>; <volume>97</volume>(<issue>5</issue>): <fpage>425</fpage>&#x02013;<lpage>428</lpage>. <pub-id pub-id-type="pmid">9490235</pub-id></mixed-citation></ref><ref id="pone.0183620.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Brevetti</surname><given-names>G</given-names></name>, <name><surname>Giugliano</surname><given-names>G</given-names></name>, <name><surname>Brevetti</surname><given-names>L</given-names></name>, <name><surname>Hiatt</surname><given-names>WR</given-names></name>. <article-title>Inflammation in peripheral arterial disease</article-title>. <source>Circulation</source>. <year>2010</year>; <volume>122</volume>: <fpage>1862</fpage>&#x02013;<lpage>1875</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCULATIONAHA.109.918417">10.1161/CIRCULATIONAHA.109.918417</ext-link></comment>
<pub-id pub-id-type="pmid">21041698</pub-id></mixed-citation></ref><ref id="pone.0183620.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Hanahan</surname><given-names>D</given-names></name>, <name><surname>Weinberg</surname><given-names>RA</given-names></name>. <article-title>The hallmarks of cancer</article-title>. <source>Cell</source>. <year>2000</year>; <volume>100</volume>(<issue>1</issue>): <fpage>57</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="pmid">10647931</pub-id></mixed-citation></ref><ref id="pone.0183620.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Pikarsky</surname><given-names>E</given-names></name>, <name><surname>Porat</surname><given-names>RM</given-names></name>, <name><surname>Stein</surname><given-names>I</given-names></name>, <name><surname>Abramovitch</surname><given-names>R</given-names></name>, <name><surname>Amit</surname><given-names>S</given-names></name>, <name><surname>Kasem</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>NF-kappaB functions as a tumour promoter in inflammation associated cancer</article-title>. <source>Nature</source>. <year>2004</year>; <volume>431</volume>(<issue>7007</issue>): <fpage>461</fpage>&#x02013;<lpage>466</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature02924">10.1038/nature02924</ext-link></comment>
<pub-id pub-id-type="pmid">15329734</pub-id></mixed-citation></ref><ref id="pone.0183620.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Karin</surname><given-names>M</given-names></name>, <name><surname>Greten</surname><given-names>FR</given-names></name>. <article-title>NF-kappaB: linking inflammation and immunity to cancer development and progression</article-title>. <source>Nat Rev Immunol</source>. <year>2005</year>: <volume>5</volume>(<issue>10</issue>): <fpage>749</fpage>&#x02013;<lpage>759</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nri1703">10.1038/nri1703</ext-link></comment>
<pub-id pub-id-type="pmid">16175180</pub-id></mixed-citation></ref><ref id="pone.0183620.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Mantovani</surname><given-names>A</given-names></name>, <name><surname>Garlanda</surname><given-names>C</given-names></name>, <name><surname>Allavena</surname><given-names>P</given-names></name>. <article-title>Molecular pathways and targets in cancer-related inflammation</article-title>. <source>Ann Med</source>. <year>2010</year>; <volume>42</volume>(<issue>3</issue>): <fpage>161</fpage>&#x02013;<lpage>170</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3109/07853890903405753">10.3109/07853890903405753</ext-link></comment>
<pub-id pub-id-type="pmid">20384432</pub-id></mixed-citation></ref><ref id="pone.0183620.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Pittet</surname><given-names>MJ</given-names></name>, <name><surname>Swirski</surname><given-names>FK</given-names></name>. <article-title>Monocytes link atherosclerosis and cancer</article-title>. <source>Eur J Immunol</source>. <year>2011</year>
<volume>41</volume>(<issue>9</issue>): <fpage>2519</fpage>&#x02013;<lpage>2522</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/eji.201141727">10.1002/eji.201141727</ext-link></comment>
<pub-id pub-id-type="pmid">21952809</pub-id></mixed-citation></ref><ref id="pone.0183620.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Hasselbalch</surname><given-names>HC</given-names></name>. <article-title>Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?</article-title>
<source>Leuk Res</source>. <year>2013</year>; <volume>37</volume>(<issue>2</issue>): <fpage>214</fpage>&#x02013;<lpage>220</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.leukres.2012.10.020">10.1016/j.leukres.2012.10.020</ext-link></comment>
<pub-id pub-id-type="pmid">23174192</pub-id></mixed-citation></ref><ref id="pone.0183620.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Hasselbalch</surname><given-names>HC</given-names></name>. <article-title>Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?</article-title>
<source>Blood</source>. <year>2012</year>; <volume>119</volume>: <fpage>3219</fpage>&#x02013;<lpage>3225</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2011-11-394775">10.1182/blood-2011-11-394775</ext-link></comment>
<pub-id pub-id-type="pmid">22318201</pub-id></mixed-citation></ref><ref id="pone.0183620.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Hasselbalch</surname><given-names>HC</given-names></name>. <article-title>The role of cytokines in the initiation and progression of myelofibrosis</article-title>. <source>Cytokine Growth Factor Rev</source>. <year>2013</year>; <volume>24</volume>(<issue>2</issue>): <fpage>133</fpage>&#x02013;<lpage>145</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cytogfr.2013.01.004">10.1016/j.cytogfr.2013.01.004</ext-link></comment>
<pub-id pub-id-type="pmid">23415024</pub-id></mixed-citation></ref><ref id="pone.0183620.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Hasselbalch</surname><given-names>HC</given-names></name>. <article-title>A role of NF-E2 in chronic inflammation and clonal evolution in essential thrombocythemia, polycythemia vera and myelofibrosis?</article-title>
<source>Leuk Res</source>. <year>2014</year>; <volume>38</volume>(<issue>2</issue>): <fpage>263</fpage>&#x02013;<lpage>266</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.leukres.2013.07.002">10.1016/j.leukres.2013.07.002</ext-link></comment>
<pub-id pub-id-type="pmid">23932394</pub-id></mixed-citation></ref><ref id="pone.0183620.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Hermouet</surname><given-names>S</given-names></name>, <name><surname>Vilaine</surname><given-names>M</given-names></name>. <article-title>The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection?</article-title>
<source>Haematologica</source>. <year>2011</year>; <volume>96</volume>(<issue>11</issue>): <fpage>1575</fpage>&#x02013;<lpage>1579</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3324/haematol.2011.055392">10.3324/haematol.2011.055392</ext-link></comment>
<pub-id pub-id-type="pmid">22058280</pub-id></mixed-citation></ref><ref id="pone.0183620.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Hermouet</surname><given-names>S</given-names></name>, <name><surname>Hasselbalch</surname><given-names>HC</given-names></name>, <name><surname>&#x0010c;oki&#x00107;</surname><given-names>V</given-names></name>. <article-title>Mediators of Inflammation in Myeloproliferative Neoplasms: State of the Art</article-title>. <source>Mediators Inflamm</source>. <year>2015</year>; <fpage>964613</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1155/2015/964613">10.1155/2015/964613</ext-link></comment>
<pub-id pub-id-type="pmid">26681841</pub-id></mixed-citation></ref><ref id="pone.0183620.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Hermouet</surname><given-names>S</given-names></name>, <name><surname>Bigot-Corbel</surname><given-names>E</given-names></name>, <name><surname>Gardie</surname><given-names>B</given-names></name>. <article-title>Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation</article-title>. <source>Mediators Inflamm</source>. <year>2015</year>; <fpage>145293</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1155/2015/145293">10.1155/2015/145293</ext-link></comment>
<pub-id pub-id-type="pmid">26538820</pub-id></mixed-citation></ref><ref id="pone.0183620.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Desterke</surname><given-names>C</given-names></name>, <name><surname>Martinaud</surname><given-names>C</given-names></name>, <name><surname>Ruzehaji</surname><given-names>N</given-names></name>, <name><surname>Le Bousse-Kerdil&#x000e8;s</surname><given-names>MC</given-names></name>. <article-title>Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis</article-title>. <source>Mediators Inflamm</source>. <year>2015</year>; <fpage>415024</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1155/2015/415024">10.1155/2015/415024</ext-link></comment>
<pub-id pub-id-type="pmid">26640324</pub-id></mixed-citation></ref><ref id="pone.0183620.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>&#x0010c;oki&#x00107;</surname><given-names>VP</given-names></name>, <name><surname>Mitrovi&#x00107;-Ajti&#x00107;</surname><given-names>O</given-names></name>, <name><surname>Beleslin-&#x0010c;oki&#x00107;</surname><given-names>BB</given-names></name>, <name><surname>Markovi&#x00107;</surname><given-names>D</given-names></name>, <name><surname>Bua&#x0010d;</surname><given-names>M</given-names></name>, <name><surname>Dikli&#x00107;</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms</article-title>. <source>Mediators Inflamm</source>. <year>2015</year>; <fpage>453020</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1155/2015/453020">10.1155/2015/453020</ext-link></comment>
<pub-id pub-id-type="pmid">26491227</pub-id></mixed-citation></ref><ref id="pone.0183620.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Geyer</surname><given-names>HL</given-names></name>, <name><surname>Dueck</surname><given-names>AC</given-names></name>, <name><surname>Scherber</surname><given-names>RM</given-names></name>, <name><surname>Mesa</surname><given-names>R</given-names></name>. <article-title>Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development</article-title>. <source>Mediators Inflamm</source>. <year>2015</year>; <fpage>284706</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1155/2015/284706">10.1155/2015/284706</ext-link></comment>
<pub-id pub-id-type="pmid">26538823</pub-id></mixed-citation></ref><ref id="pone.0183620.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Koschmieder</surname><given-names>S</given-names></name>, <name><surname>Mughal</surname><given-names>TI</given-names></name>, <name><surname>Hasselbalch</surname><given-names>HC</given-names></name>, <name><surname>Barosi</surname><given-names>G</given-names></name>, <name><surname>Valent</surname><given-names>P</given-names></name>, <name><surname>Kiladjian</surname><given-names>JJ</given-names></name>, <etal>et al</etal>
<article-title>Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both</article-title>. <source>Leukemia</source>. <year>2016</year>; <volume>30</volume>(<issue>5</issue>): <fpage>1018</fpage>&#x02013;<lpage>1024</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/leu.2016.12">10.1038/leu.2016.12</ext-link></comment>
<pub-id pub-id-type="pmid">26854026</pub-id></mixed-citation></ref><ref id="pone.0183620.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Panteli</surname><given-names>KE</given-names></name>, <name><surname>Hatzimichael</surname><given-names>EC</given-names></name>, <name><surname>Bouranta</surname><given-names>PK</given-names></name>, <name><surname>Katsaraki</surname><given-names>A</given-names></name>, <name><surname>Seferiadis</surname><given-names>K</given-names></name>, <name><surname>Stebbing</surname></name>, <etal>et al</etal>
<article-title>Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases</article-title>. <source>Br J Haematol</source>. <year>2005</year>; <volume>130</volume>: <fpage>709</fpage>&#x02013;<lpage>715</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1365-2141.2005.05674.x">10.1111/j.1365-2141.2005.05674.x</ext-link></comment>
<pub-id pub-id-type="pmid">16115126</pub-id></mixed-citation></ref><ref id="pone.0183620.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Barbui</surname><given-names>T</given-names></name>, <name><surname>Carobbio</surname><given-names>A</given-names></name>, <name><surname>Finazzi</surname><given-names>G</given-names></name>, <name><surname>Vannucchi</surname><given-names>AM</given-names></name>, <name><surname>Barosi</surname><given-names>G</given-names></name>, <name><surname>Antonioli</surname><given-names>E</given-names></name>
<etal>et al</etal>
<article-title>Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3</article-title>. <source>Haematologica</source>. <year>2011</year>; <volume>96</volume>: <fpage>315</fpage>&#x02013;<lpage>318</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3324/haematol.2010.031070">10.3324/haematol.2010.031070</ext-link></comment>
<pub-id pub-id-type="pmid">21173097</pub-id></mixed-citation></ref><ref id="pone.0183620.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Barbui</surname><given-names>T</given-names></name>, <name><surname>Carobbio</surname><given-names>A</given-names></name>, <name><surname>Finazzi</surname><given-names>G</given-names></name>, <name><surname>Guglielmelli</surname><given-names>P</given-names></name>, <name><surname>Salmoiraghi</surname><given-names>S</given-names></name>, <name><surname>Rosti</surname><given-names>V</given-names></name>
<etal>et al</etal>, <article-title>Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis</article-title>. <source>Leukemia</source>. <year>2013</year>; <volume>27</volume>(<issue>10</issue>): <fpage>2084</fpage>&#x02013;<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/leu.2013.207">10.1038/leu.2013.207</ext-link></comment>
<pub-id pub-id-type="pmid">23828261</pub-id></mixed-citation></ref><ref id="pone.0183620.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Verstovsek</surname><given-names>S</given-names></name>, <name><surname>Kantarjian</surname><given-names>H</given-names></name>, <name><surname>Mesa</surname><given-names>RA</given-names></name>, <name><surname>Pardanani</surname><given-names>AD</given-names></name>, <name><surname>Cortes-Franco</surname><given-names>J</given-names></name>, <name><surname>Thomas</surname><given-names>DA</given-names></name>, <etal>et al</etal>
<article-title>Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis</article-title>. <source>N Engl J Med</source>. <year>2010</year>; <volume>363</volume>: <fpage>1117</fpage>&#x02013;<lpage>1127</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa1002028">10.1056/NEJMoa1002028</ext-link></comment>
<pub-id pub-id-type="pmid">20843246</pub-id></mixed-citation></ref><ref id="pone.0183620.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Tefferi</surname><given-names>A</given-names></name>, <name><surname>Vaidya</surname><given-names>R</given-names></name>, <name><surname>Caramazza</surname><given-names>D</given-names></name>, <name><surname>Finke</surname><given-names>C</given-names></name>, <name><surname>Lasho</surname><given-names>T</given-names></name>, <name><surname>Pardanani</surname><given-names>A</given-names></name>. <article-title>Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study</article-title>. <source>J Clin Oncol</source>
<volume>29</volume>
<year>2011</year>; <fpage>1356</fpage>&#x02013;<lpage>1363</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1200/JCO.2010.32.9490">10.1200/JCO.2010.32.9490</ext-link></comment>
<pub-id pub-id-type="pmid">21300928</pub-id></mixed-citation></ref><ref id="pone.0183620.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Vaidya</surname><given-names>R</given-names></name>, <name><surname>Gangat</surname><given-names>N</given-names></name>, <name><surname>Jimma</surname><given-names>T</given-names></name>, <name><surname>Finke</surname><given-names>CM</given-names></name>, <name><surname>Lasho</surname><given-names>TL</given-names></name>, <name><surname>Pardanani</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis</article-title>. <source>Am J Hematol</source>. <year>2012</year>; <volume>87</volume>(<issue>11</issue>): <fpage>1003</fpage>&#x02013;<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/ajh.23295">10.1002/ajh.23295</ext-link></comment>
<pub-id pub-id-type="pmid">22965887</pub-id></mixed-citation></ref><ref id="pone.0183620.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Pourcelot</surname><given-names>E</given-names></name>, <name><surname>Trocme</surname><given-names>C</given-names></name>, <name><surname>Mondet</surname><given-names>J</given-names></name>, <name><surname>Bailly</surname><given-names>S</given-names></name>, <name><surname>Toussaint</surname><given-names>B</given-names></name>, <name><surname>Mossuz</surname><given-names>P</given-names></name>. <article-title>Cytokine profiles in polycythemia vera and essential thrombocythemia patients: Clinical implications</article-title>. <source>Experimental Hematol</source>. <year>2014</year>; <volume>42</volume>: <fpage>360</fpage>&#x02013;<lpage>368</lpage>.</mixed-citation></ref><ref id="pone.0183620.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Christensen</surname><given-names>AS</given-names></name>, <name><surname>M&#x000f8;ller</surname><given-names>JB</given-names></name>, <name><surname>Hasselbalch</surname><given-names>HC</given-names></name>. <article-title>Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms</article-title>. <source>Leuk Res</source>. <year>2014</year>; <volume>38</volume>(<issue>4</issue>): <fpage>490</fpage>&#x02013;<lpage>495</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.leukres.2014.01.014">10.1016/j.leukres.2014.01.014</ext-link></comment>
<pub-id pub-id-type="pmid">24630365</pub-id></mixed-citation></ref><ref id="pone.0183620.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Bak</surname><given-names>M</given-names></name>, <name><surname>S&#x000f8;rensen</surname><given-names>TL</given-names></name>, <name><surname>Meulengracht Flachs</surname><given-names>E</given-names></name>, <name><surname>Zwisler</surname><given-names>AD</given-names></name>, <name><surname>Juel</surname><given-names>K</given-names></name>, <name><surname>Frederiksen</surname><given-names>H</given-names></name>, <etal>et al</etal>: <article-title>Age-Related Macular Degeneration in Patients with Chronic Myeloproliferative Neoplasms: A Nationwide Population-Based Cohort Study</article-title>. <source>JAMA Ophthalmol</source>. <year>2017</year>; <volume>135</volume>(<issue>8</issue>):<fpage>835</fpage>&#x02013;<lpage>843</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jamaophthalmol.2017.2011">10.1001/jamaophthalmol.2017.2011</ext-link></comment>
<pub-id pub-id-type="pmid">28655032</pub-id></mixed-citation></ref><ref id="pone.0183620.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Hasselbalch</surname><given-names>HC</given-names></name>. <article-title>Smoking as a contributing factor for development of polycythemia vera and related neoplasms</article-title>. <source>Leuk Res</source>. <year>2015</year>; 015 <month>9</month>
<day>9</day>.</mixed-citation></ref><ref id="pone.0183620.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Lindholm S&#x000f8;rensen</surname><given-names>A</given-names></name>, <name><surname>Hasselbalch</surname><given-names>HC</given-names></name>. <article-title>Smoking and Philadelphia-negative chronic myeloproliferative neoplasms</article-title>. <source>Eur J Haematol</source>. <year>2016</year>; <volume>97</volume>(<issue>1</issue>): <fpage>63</fpage>&#x02013;<lpage>69</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/ejh.12684">10.1111/ejh.12684</ext-link></comment>
<pub-id pub-id-type="pmid">26384085</pub-id></mixed-citation></ref><ref id="pone.0183620.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Andersen</surname><given-names>CL</given-names></name>, <name><surname>Bj&#x000f8;rn</surname><given-names>ME</given-names></name>, <name><surname>McMullin</surname><given-names>MF</given-names></name>, <name><surname>Harrison</surname><given-names>C</given-names></name>, <name><surname>Samuelsson</surname><given-names>J</given-names></name>,<name><surname>Ejerblad</surname><given-names>E</given-names></name>
<etal>et al</etal>
<article-title>Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat</article-title>. <source>Leuk Res</source>. <year>2014</year>; <volume>38</volume>(<issue>7</issue>): <fpage>816</fpage>&#x02013;<lpage>821</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.leukres.2014.04.002">10.1016/j.leukres.2014.04.002</ext-link></comment>
<pub-id pub-id-type="pmid">24836761</pub-id></mixed-citation></ref><ref id="pone.0183620.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Bj&#x000f8;rn</surname><given-names>ME</given-names></name>, <name><surname>Andersen</surname><given-names>CL</given-names></name>, <name><surname>Jensen</surname><given-names>MK</given-names></name>, <name><surname>Hasselbalch</surname><given-names>HC</given-names></name>. <article-title>Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state</article-title>. <source>Eur J Haematol</source>. <year>2014</year>; <volume>93</volume>(<issue>3</issue>): <fpage>224</fpage>&#x02013;<lpage>228</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/ejh.12332">10.1111/ejh.12332</ext-link></comment>
<pub-id pub-id-type="pmid">24689875</pub-id></mixed-citation></ref><ref id="pone.0183620.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Bj&#x000f8;rn</surname><given-names>ME</given-names></name>, <name><surname>Hasselbalch</surname><given-names>HC</given-names></name>. <article-title>The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms</article-title>. <source>Mediators Inflamm</source>. <year>2015</year>; <fpage>648090</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1155/2015/648090">10.1155/2015/648090</ext-link></comment>
<pub-id pub-id-type="pmid">26538833</pub-id></mixed-citation></ref><ref id="pone.0183620.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Fleischman</surname><given-names>AG</given-names></name>, <name><surname>Aichberger</surname><given-names>KJ</given-names></name>, <name><surname>Luty</surname><given-names>SB</given-names></name>, <name><surname>Bumm</surname><given-names>TG</given-names></name>, <name><surname>Petersen</surname><given-names>CL</given-names></name>, <name><surname>Doratotaj</surname><given-names>S</given-names></name>, <etal>et al</etal>: <article-title>TNF&#x003b1; facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms</article-title>. <source>Blood</source>. <year>2011</year>; <volume>118</volume>: <fpage>6392</fpage>&#x02013;<lpage>6398</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2011-04-348144">10.1182/blood-2011-04-348144</ext-link></comment>
<pub-id pub-id-type="pmid">21860020</pub-id></mixed-citation></ref><ref id="pone.0183620.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Lu</surname><given-names>M</given-names></name>, <name><surname>Xia</surname><given-names>L</given-names></name>, <name><surname>Liu</surname><given-names>YC</given-names></name>, <name><surname>Hochman</surname><given-names>T</given-names></name>
<etal>et al</etal>: <article-title>Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells</article-title>. <source>Blood</source>. <year>2015</year>; <volume>126</volume>: <fpage>972</fpage>&#x02013;<lpage>982</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2014-12-618595">10.1182/blood-2014-12-618595</ext-link></comment>
<pub-id pub-id-type="pmid">26022238</pub-id></mixed-citation></ref><ref id="pone.0183620.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Kleppe</surname><given-names>M</given-names></name>, <name><surname>Kwak</surname><given-names>M</given-names></name>, <name><surname>Koppikar</surname><given-names>P</given-names></name>, <name><surname>Riester</surname><given-names>M</given-names></name>, <name><surname>Keller</surname><given-names>M</given-names></name>, <name><surname>Bastian</surname><given-names>L</given-names></name>
<etal>et al</etal>
<article-title>JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response</article-title>. <source>Cancer Discov</source>. <year>2015</year>; <volume>5</volume>: <fpage>316</fpage>&#x02013;<lpage>331</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1158/2159-8290.CD-14-0736">10.1158/2159-8290.CD-14-0736</ext-link></comment>
<pub-id pub-id-type="pmid">25572172</pub-id></mixed-citation></ref><ref id="pone.0183620.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Kaufmann</surname><given-names>KB</given-names></name>, <name><surname>Grunder</surname><given-names>A</given-names></name>, <name><surname>Hadlich</surname><given-names>T</given-names></name>, <name><surname>Wehrle</surname><given-names>J</given-names></name>, <name><surname>Gothwal</surname><given-names>M</given-names></name>, <name><surname>Bogeska</surname><given-names>R</given-names></name>, <etal>et al</etal>: <article-title>A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2</article-title>. <source>J Exp Med</source>. <year>2012</year>; <volume>209</volume>: <fpage>35</fpage>&#x02013;<lpage>50</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1084/jem.20110540">10.1084/jem.20110540</ext-link></comment>
<pub-id pub-id-type="pmid">22231305</pub-id></mixed-citation></ref><ref id="pone.0183620.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Jutzi</surname><given-names>JS</given-names></name>, <name><surname>Bogeska</surname><given-names>R</given-names></name>, <name><surname>Nikoloski</surname><given-names>G</given-names></name>, <name><surname>Schmid</surname><given-names>CA</given-names></name>, <name><surname>Seeger</surname><given-names>TS</given-names></name>, <name><surname>Stegelmann</surname><given-names>F</given-names></name>
<etal>et al</etal>: <article-title>MPN patients harbor recurrent truncating mutations in transcription factor NF-E2</article-title>. <source>J Exp Med</source>. <year>2013</year>; <volume>210</volume>: <fpage>1003</fpage>&#x02013;<lpage>1019</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1084/jem.20120521">10.1084/jem.20120521</ext-link></comment>
<pub-id pub-id-type="pmid">23589569</pub-id></mixed-citation></ref><ref id="pone.0183620.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Jutzi</surname><given-names>JS</given-names></name>, <name><surname>Pahl</surname><given-names>HL</given-names></name>. <article-title>The hen or the egg: inflammatory aspects of murine MPN models</article-title>. <source>Mediators Inflamm</source>. <year>2015</year>; <volume>2015</volume>:<fpage>101987</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1155/2015/101987">10.1155/2015/101987</ext-link></comment>
<pub-id pub-id-type="pmid">26543325</pub-id></mixed-citation></ref><ref id="pone.0183620.ref060"><label>60</label><mixed-citation publication-type="journal"><name><surname>Wehrle</surname><given-names>J</given-names></name>, <name><surname>Seeger</surname><given-names>TS</given-names></name>, <name><surname>Schwemmers</surname><given-names>S</given-names></name>, <name><surname>Pfeifer</surname><given-names>D</given-names></name>, <name><surname>Bulashevska</surname><given-names>A</given-names></name>, <name><surname>Pahl</surname><given-names>HL</given-names></name>. <article-title>Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms</article-title>. <source>Haematologica</source>. <year>2013</year>; <volume>98</volume>: <fpage>1073</fpage>&#x02013;<lpage>1080</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3324/haematol.2012.071183">10.3324/haematol.2012.071183</ext-link></comment>
<pub-id pub-id-type="pmid">23445878</pub-id></mixed-citation></ref><ref id="pone.0183620.ref061"><label>61</label><mixed-citation publication-type="journal"><name><surname>Roelz</surname><given-names>R</given-names></name>, <name><surname>Pilz</surname><given-names>IH</given-names></name>, <name><surname>Mutschler</surname><given-names>M</given-names></name>, <name><surname>Pahl</surname><given-names>HL</given-names></name>. <article-title>Of mice and men: human RNA polymerase III promoter U6 is more efficient than its murine homologue for shRNA expression from a lentiviral vector in both human and murine progenitor cells</article-title>. <source>Exp Hematol</source>. <year>2010</year>; <volume>38</volume>: <fpage>792</fpage>&#x02013;<lpage>797</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.exphem.2010.05.005">10.1016/j.exphem.2010.05.005</ext-link></comment>
<pub-id pub-id-type="pmid">20685233</pub-id></mixed-citation></ref><ref id="pone.0183620.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Liu</surname><given-names>X</given-names></name>, <name><surname>McHale</surname><given-names>C</given-names></name>, <name><surname>Li</surname><given-names>R</given-names></name>, <name><surname>Zhang</surname><given-names>L</given-names></name>, <name><surname>Wu</surname><given-names>Y</given-names></name>
<etal>et al</etal>
<article-title>Bone marrow injury induced via oxidative stress in mice by inhalation exposure to formaldehyde</article-title>. <source>PLoS One</source>. <year>2013</year>; <volume>8</volume>: <fpage>e74974</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0074974">10.1371/journal.pone.0074974</ext-link></comment>
<pub-id pub-id-type="pmid">24040369</pub-id></mixed-citation></ref><ref id="pone.0183620.ref063"><label>63</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Q</given-names></name>, <name><surname>Zhao</surname><given-names>K</given-names></name>, <name><surname>Shen</surname><given-names>Q</given-names></name>, <name><surname>Han</surname><given-names>Y</given-names></name>, <name><surname>Gu</surname><given-names>Y</given-names></name>, <name><surname>Li</surname><given-names>X</given-names></name>, <etal>et al</etal>: <article-title>Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6</article-title>. <source>Nature</source>. <year>2015</year>; <volume>525</volume>: <fpage>389</fpage>&#x02013;<lpage>393</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature15252">10.1038/nature15252</ext-link></comment>
<pub-id pub-id-type="pmid">26287468</pub-id></mixed-citation></ref><ref id="pone.0183620.ref064"><label>64</label><mixed-citation publication-type="journal"><name><surname>Skov</surname><given-names>V</given-names></name>, <name><surname>Larsen</surname><given-names>TS</given-names></name>, <name><surname>Thomassen</surname><given-names>M</given-names></name>, <name><surname>Riley</surname><given-names>CH</given-names></name>, <name><surname>Jensen</surname><given-names>MK</given-names></name>, <name><surname>Bjerrum</surname><given-names>OW</given-names></name>, <etal>et al</etal>: <article-title>Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis</article-title>. <source>Eur J Haematol</source>. <year>2011</year>; <volume>87</volume>(<issue>1</issue>): <fpage>54</fpage>&#x02013;<lpage>60</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1600-0609.2011.01618.x">10.1111/j.1600-0609.2011.01618.x</ext-link></comment>
<pub-id pub-id-type="pmid">21447007</pub-id></mixed-citation></ref><ref id="pone.0183620.ref065"><label>65</label><mixed-citation publication-type="journal"><name><surname>Skov</surname><given-names>V</given-names></name>, <name><surname>Riley</surname><given-names>CH</given-names></name>, <name><surname>Thomassen</surname><given-names>M</given-names></name>, <name><surname>Larsen</surname><given-names>TS</given-names></name>, <name><surname>Jensen</surname><given-names>MK</given-names></name>, <name><surname>Bjerrum</surname><given-names>OW</given-names></name>, <etal>et al</etal>: <article-title>Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis</article-title>. <source>Leuk Lymphoma</source>. <year>2013</year>; <volume>54</volume>(<issue>10</issue>): <fpage>2269</fpage>&#x02013;<lpage>2273</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3109/10428194.2013.764417">10.3109/10428194.2013.764417</ext-link></comment>
<pub-id pub-id-type="pmid">23302045</pub-id></mixed-citation></ref><ref id="pone.0183620.ref066"><label>66</label><mixed-citation publication-type="journal"><name><surname>Skov</surname><given-names>V</given-names></name>, <name><surname>Thomassen</surname><given-names>M</given-names></name>, <name><surname>Riley</surname><given-names>CH</given-names></name>, <name><surname>Jensen</surname><given-names>MK</given-names></name>, <name><surname>Bjerrum</surname><given-names>OW</given-names></name>, <name><surname>Kruse</surname><given-names>TA</given-names></name>, <etal>et al</etal>: <article-title>Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis</article-title>. <source>Exp. Hematol</source>. <year>2012</year>; <volume>40</volume>(<issue>9</issue>): <fpage>771</fpage>&#x02013;<lpage>780</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.exphem.2012.05.011">10.1016/j.exphem.2012.05.011</ext-link></comment>
<pub-id pub-id-type="pmid">22659388</pub-id></mixed-citation></ref><ref id="pone.0183620.ref067"><label>67</label><mixed-citation publication-type="journal"><name><surname>Skov</surname><given-names>V</given-names></name>, <name><surname>Larsen</surname><given-names>TS</given-names></name>, <name><surname>Thomassen</surname><given-names>M</given-names></name>, <name><surname>Riley</surname><given-names>CH</given-names></name>, <name><surname>Jensen</surname><given-names>MK</given-names></name>, <name><surname>Bjerrum</surname><given-names>OW</given-names></name>, <etal>et al</etal>
<article-title>Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance</article-title>. <source>Leuk Res</source>. <year>2012</year>; <volume>36</volume>(<issue>11</issue>): <fpage>1387</fpage>&#x02013;<lpage>1392</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.leukres.2012.07.009">10.1016/j.leukres.2012.07.009</ext-link></comment>
<pub-id pub-id-type="pmid">22877729</pub-id></mixed-citation></ref><ref id="pone.0183620.ref068"><label>68</label><mixed-citation publication-type="journal"><name><surname>Hasselbalch</surname><given-names>HC</given-names></name>, <name><surname>Thomassen</surname><given-names>M</given-names></name>, <name><surname>Riley</surname><given-names>CH</given-names></name>, <name><surname>Kj&#x000e6;r</surname><given-names>L</given-names></name>, <name><surname>Larsen</surname><given-names>TS</given-names></name>, <name><surname>Jensen</surname><given-names>MK</given-names></name>, <etal>et al</etal>
<article-title>Whole blood transcriptional profiling reveals deregulation of oxidative and antioxidative defence genes in myelofibrosis and related neoplasms. Potential implications of downregulation of Nrf2 for genomic instability and disease progression</article-title>. <source>PLoS One</source>. <year>2014</year>; <day>14</day>;<volume>9</volume>(<issue>11</issue>):<fpage>e112786</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0112786">10.1371/journal.pone.0112786</ext-link></comment>
<pub-id pub-id-type="pmid">25397683</pub-id></mixed-citation></ref><ref id="pone.0183620.ref069"><label>69</label><mixed-citation publication-type="journal"><name><surname>Skov</surname><given-names>V</given-names></name>, <name><surname>Burton</surname><given-names>M</given-names></name>, <name><surname>Thomassen</surname><given-names>M</given-names></name>, <name><surname>Larsen</surname><given-names>TS</given-names></name>, <name><surname>Riley</surname><given-names>CH</given-names></name>, <name><surname>Madelung</surname><given-names>AB</given-names></name>
<etal>et al</etal>
<article-title>A 7-Gene Signature Depicts The Biochemical Profile of Early Prefibrotic Myelofibrosis</article-title>. <source>Plos One</source>. <year>2016</year>; <volume>11</volume>(<issue>8</issue>): <fpage>e0161570</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0161570">10.1371/journal.pone.0161570</ext-link></comment>
<pub-id pub-id-type="pmid">27579896</pub-id></mixed-citation></ref><ref id="pone.0183620.ref070"><label>70</label><mixed-citation publication-type="journal"><name><surname>Ciaffoni</surname><given-names>F</given-names></name>, <name><surname>Cassella</surname><given-names>E</given-names></name>, <name><surname>Varricchio</surname><given-names>L</given-names></name>, <name><surname>Massa</surname><given-names>M</given-names></name>, <name><surname>Barosi</surname><given-names>G</given-names></name>, <name><surname>Migliaccio</surname><given-names>AR</given-names></name>. <article-title>Activation of non-canonical TGF-&#x003b2;1 signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis</article-title>. <source>Blood Cells Mol Dis</source>. <year>2015</year>; <volume>54</volume>(<issue>3</issue>): <fpage>234</fpage>&#x02013;<lpage>41</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.bcmd.2014.12.005">10.1016/j.bcmd.2014.12.005</ext-link></comment>
<pub-id pub-id-type="pmid">25703685</pub-id></mixed-citation></ref><ref id="pone.0183620.ref071"><label>71</label><mixed-citation publication-type="journal"><name><surname>Riley</surname><given-names>CH</given-names></name>, <name><surname>Jensen</surname><given-names>MK</given-names></name>, <name><surname>Brimnes</surname><given-names>MK</given-names></name>, <name><surname>Hasselbalch</surname><given-names>HC</given-names></name>, <name><surname>Bjerrum</surname><given-names>OW</given-names></name>, <name><surname>Straten</surname><given-names>PT</given-names></name>, <etal>et al</etal>
<article-title>Increase in circulating CD4(+) CD25(+) Foxp3(+) T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-alpha</article-title>. <source>Blood</source>. <year>2011</year>; <volume>118</volume>(<issue>8</issue>): <fpage>2170</fpage>&#x02013;<lpage>2173</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2011-03-340992">10.1182/blood-2011-03-340992</ext-link></comment>
<pub-id pub-id-type="pmid">21708889</pub-id></mixed-citation></ref><ref id="pone.0183620.ref072"><label>72</label><mixed-citation publication-type="journal"><name><surname>Riley</surname><given-names>CH</given-names></name>, <name><surname>Hansen</surname><given-names>M</given-names></name>, <name><surname>Brimnes</surname><given-names>MK</given-names></name>, <name><surname>Hasselbalch</surname><given-names>HC</given-names></name>, <name><surname>Bjerrum</surname><given-names>OW</given-names></name>, <name><surname>Svane</surname><given-names>IM</given-names></name>, <etal>et al</etal>
<article-title>Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-&#x003b1;</article-title>. <source>Eur J Haematol</source>. <year>2015</year>; <volume>94</volume>(<issue>3</issue>): <fpage>227</fpage>&#x02013;<lpage>234</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/ejh.12420">10.1111/ejh.12420</ext-link></comment>
<pub-id pub-id-type="pmid">25082025</pub-id></mixed-citation></ref><ref id="pone.0183620.ref073"><label>73</label><mixed-citation publication-type="journal"><name><surname>Riley</surname><given-names>CH</given-names></name>, <name><surname>Brimnes</surname><given-names>MK</given-names></name>, <name><surname>Hansen</surname><given-names>M</given-names></name>, <name><surname>Jensen</surname><given-names>MK</given-names></name>, <name><surname>Hasselbalch</surname><given-names>HC</given-names></name>, <name><surname>Kjaer</surname><given-names>L</given-names></name>, <etal>et al</etal>: <article-title>Interferon-alpha induces marked alterations in circulating regulatory T cells, NK cell subsets and dendritic cells in patients with JAK2 -positive essential thrombocythemia and polycythemia vera</article-title>. <source>Eur J Haematol</source>. <year>2016</year>; <volume>97</volume>(<issue>1</issue>): <fpage>83</fpage>&#x02013;<lpage>92</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/ejh.12687">10.1111/ejh.12687</ext-link></comment>
<pub-id pub-id-type="pmid">26385526</pub-id></mixed-citation></ref><ref id="pone.0183620.ref074"><label>74</label><mixed-citation publication-type="journal"><name><surname>Barosi</surname><given-names>G</given-names></name>. <article-title>An immune dysregulation in MPN</article-title>. <source>Curr Hematol Malig Rep</source>. <year>2014</year>; <volume>9</volume>(<issue>4</issue>): <fpage>331</fpage>&#x02013;<lpage>339</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s11899-014-0227-0">10.1007/s11899-014-0227-0</ext-link></comment>
<pub-id pub-id-type="pmid">25139710</pub-id></mixed-citation></ref><ref id="pone.0183620.ref075"><label>75</label><mixed-citation publication-type="journal"><name><surname>Titmarsh</surname><given-names>GJ</given-names></name>, <name><surname>McMullin</surname><given-names>MF</given-names></name>, <name><surname>McShane</surname><given-names>CM</given-names></name>, <name><surname>Clarke</surname><given-names>M</given-names></name>, <name><surname>Engels</surname><given-names>EA</given-names></name>, <name><surname>Anderson</surname><given-names>LA</given-names></name>, <etal>et al</etal>: <article-title>Community-acquired infections and their association with myeloid malignancies</article-title>. <source>Cancer Epidemiol</source>. <year>2014</year>; <volume>38</volume>(<issue>1</issue>): <fpage>56</fpage>&#x02013;<lpage>61</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.canep.2013.10.009">10.1016/j.canep.2013.10.009</ext-link></comment>
<pub-id pub-id-type="pmid">24275260</pub-id></mixed-citation></ref><ref id="pone.0183620.ref076"><label>76</label><mixed-citation publication-type="journal"><name><surname>Nielsen</surname><given-names>C</given-names></name>, <name><surname>Birgens</surname><given-names>HS</given-names></name>, <name><surname>Nordestgaard</surname><given-names>BG</given-names></name>, <name><surname>Kjaer</surname><given-names>L</given-names></name>, <name><surname>Bojesen</surname><given-names>SE</given-names></name>. <article-title>The JAK2 V617F somatic mutation, mortality and cancer risk in the general population</article-title>. <source>Haematologica</source>. <year>2011</year>; <volume>96</volume>(<issue>3</issue>): <fpage>450</fpage>&#x02013;<lpage>453</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3324/haematol.2010.033191">10.3324/haematol.2010.033191</ext-link></comment>
<pub-id pub-id-type="pmid">21160067</pub-id></mixed-citation></ref><ref id="pone.0183620.ref077"><label>77</label><mixed-citation publication-type="journal"><name><surname>Nielsen</surname><given-names>C</given-names></name>, <name><surname>Bojesen</surname><given-names>SE</given-names></name>, <name><surname>Nordestgaard</surname><given-names>BG</given-names></name>, <name><surname>Kofoed</surname><given-names>KF</given-names></name>, <name><surname>Birgens</surname><given-names>HS</given-names></name>. <article-title>JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate</article-title>. <source>Haematologica</source>. <year>2014</year>; <volume>99</volume>(<issue>9</issue>): <fpage>1448</fpage>&#x02013;<lpage>1455</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3324/haematol.2014.107631">10.3324/haematol.2014.107631</ext-link></comment>
<pub-id pub-id-type="pmid">24907356</pub-id></mixed-citation></ref><ref id="pone.0183620.ref078"><label>78</label><mixed-citation publication-type="journal"><name><surname>Haeno</surname><given-names>H</given-names></name>, <name><surname>Levine</surname><given-names>RL</given-names></name>, <name><surname>Gilliland</surname><given-names>DG</given-names></name>, <name><surname>Michor</surname><given-names>F</given-names></name>. <article-title>A progenitor cell origin of myeloid malignancies</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2009</year>; <volume>106</volume>(<issue>39</issue>): <fpage>16616</fpage>&#x02013;<lpage>16621</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.0908107106">10.1073/pnas.0908107106</ext-link></comment>
<pub-id pub-id-type="pmid">19805346</pub-id></mixed-citation></ref><ref id="pone.0183620.ref079"><label>79</label><mixed-citation publication-type="journal"><name><surname>Attolini</surname><given-names>CS</given-names></name>, <name><surname>Cheng</surname><given-names>YK</given-names></name>, <name><surname>Beroukhim</surname><given-names>R</given-names></name>, <name><surname>Getz</surname><given-names>G</given-names></name>, <name><surname>Abdel-Wahab</surname><given-names>O</given-names></name>, <name><surname>Levine</surname><given-names>RL</given-names></name>, <etal>et al</etal>
<article-title>A mathematical framework to determine the temporal sequence of somatic genetic events in cancer</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2010</year>; <volume>107</volume>(<issue>41</issue>): <fpage>17604</fpage>&#x02013;<lpage>17609</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.1009117107">10.1073/pnas.1009117107</ext-link></comment>
<pub-id pub-id-type="pmid">20864632</pub-id></mixed-citation></ref><ref id="pone.0183620.ref080"><label>80</label><mixed-citation publication-type="journal"><name><surname>Michor</surname><given-names>F</given-names></name>, <name><surname>Iwasa</surname><given-names>Y</given-names></name>, <name><surname>Nowak</surname><given-names>MA</given-names></name>. <article-title>Dynamics of cancer progression</article-title>. <source>Nature Reviews Cancer</source>. <year>2004</year>; <volume>4</volume>: <fpage>197</fpage>&#x02013;<lpage>205</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrc1295">10.1038/nrc1295</ext-link></comment>
<pub-id pub-id-type="pmid">14993901</pub-id></mixed-citation></ref><ref id="pone.0183620.ref081"><label>81</label><mixed-citation publication-type="journal"><name><surname>Michor</surname><given-names>F</given-names></name>, <name><surname>Hughes</surname><given-names>TP</given-names></name>, <name><surname>Iwasa</surname><given-names>Y</given-names></name>, <name><surname>Branford</surname><given-names>S</given-names></name>, <name><surname>Shah</surname><given-names>NP</given-names></name>, <name><surname>Sawyers</surname><given-names>CL</given-names></name>. <article-title>Dynamics of chronic myeloid leukaemia</article-title>. <source>Nature</source>. <year>2005</year>; <volume>435</volume>: <fpage>1267</fpage>&#x02013;<lpage>1270</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature03669">10.1038/nature03669</ext-link></comment>
<pub-id pub-id-type="pmid">15988530</pub-id></mixed-citation></ref><ref id="pone.0183620.ref082"><label>82</label><mixed-citation publication-type="journal"><name><surname>De Pillis</surname><given-names>LG</given-names></name>, <name><surname>Radunskaya</surname><given-names>AE</given-names></name>, <name><surname>Wiseman</surname><given-names>CL</given-names></name>. <article-title>A validated mathematical model of cell-mediated immune response to tumor growth</article-title>. <source>Cancer Research</source>. <year>2005</year>; <volume>65</volume>(<issue>17</issue>): <fpage>7950</fpage>&#x02013;<lpage>7958</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1158/0008-5472.CAN-05-0564">10.1158/0008-5472.CAN-05-0564</ext-link></comment>
<pub-id pub-id-type="pmid">16140967</pub-id></mixed-citation></ref><ref id="pone.0183620.ref083"><label>83</label><mixed-citation publication-type="journal"><name><surname>Michor</surname><given-names>F</given-names></name>. <article-title>Mathematical models of cancer stem cells</article-title>. <source>J Clin Oncol</source>. <year>2008</year>; <volume>26</volume>(<issue>17</issue>): <fpage>2854</fpage>&#x02013;<lpage>2861</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1200/JCO.2007.15.2421">10.1200/JCO.2007.15.2421</ext-link></comment>
<pub-id pub-id-type="pmid">18539964</pub-id></mixed-citation></ref><ref id="pone.0183620.ref084"><label>84</label><mixed-citation publication-type="journal"><name><surname>Stiehl</surname><given-names>T</given-names></name>, <name><surname>Marciniak-Czochra</surname><given-names>A</given-names></name>. <article-title>Characterization of stem cells using mathematical models of multistage cell lineages</article-title>. <source>Mathematical and Computer Modelling</source>. <year>2011</year>; <volume>53</volume>(<issue>7&#x02013;8</issue>): <fpage>1505</fpage>&#x02013;<lpage>1517</lpage>.</mixed-citation></ref><ref id="pone.0183620.ref085"><label>85</label><mixed-citation publication-type="journal"><name><surname>Stiehl</surname><given-names>T</given-names></name>, <name><surname>Marciniak-Czochra</surname><given-names>A</given-names></name>. <article-title>Mathematical Modeling of Leukemogenesis and Cancer Stem Cell Dynamics</article-title>. <source>Math Model Nat Phenom</source>. <year>2012</year>; <volume>7</volume>(<issue>1</issue>): <fpage>166</fpage>&#x02013;<lpage>202</lpage>.</mixed-citation></ref><ref id="pone.0183620.ref086"><label>86</label><mixed-citation publication-type="journal"><name><surname>Gentry</surname><given-names>SN</given-names></name>, <name><surname>Jackson</surname><given-names>TL</given-names></name>. <article-title>A mathematical model of cancer stem cell driven tumor initiation: implications of niche size and loss of homeostatic regulatory mechanisms</article-title>. <source>Plos One</source>. <year>2013</year>; <volume>8</volume>(<issue>8</issue>): <fpage>e71128</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0071128">10.1371/journal.pone.0071128</ext-link></comment>
<pub-id pub-id-type="pmid">23990931</pub-id></mixed-citation></ref><ref id="pone.0183620.ref087"><label>87</label><mixed-citation publication-type="journal"><name><surname>Walenda</surname><given-names>T</given-names></name>, <name><surname>Stiehl</surname><given-names>T</given-names></name>, <name><surname>Braun</surname><given-names>H</given-names></name>, <name><surname>Fr&#x000f6;bel</surname><given-names>J</given-names></name>, <name><surname>Ho</surname><given-names>AD</given-names></name>, <name><surname>Schroeder</surname><given-names>T</given-names></name>, <etal>et al</etal>: <article-title>Feedback Signals in Myelodysplastic Syndromes: Increased Self-Renewal of the Malignant Clone Suppresses Normal Hematopoiesis</article-title>. <source>PLoS Comput Biol</source>. <year>2014</year>; <volume>10</volume>(<issue>4</issue>): <fpage>e1003599</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pcbi.1003599">10.1371/journal.pcbi.1003599</ext-link></comment>
<pub-id pub-id-type="pmid">24763223</pub-id></mixed-citation></ref><ref id="pone.0183620.ref088"><label>88</label><mixed-citation publication-type="journal"><name><surname>Stiehl</surname><given-names>T</given-names></name>, <name><surname>Baran</surname><given-names>N</given-names></name>, <name><surname>Ho</surname><given-names>AD</given-names></name>, <name><surname>Marciniak-Czochra</surname><given-names>A</given-names></name>. <article-title>Cell Division Patterns in Acute Myeloid Leukemia Stem-like Cells Determine Clinical Course: A Model to Predict Patient Survival</article-title>. <source>Cancer Research</source>. <year>2015</year>; <volume>75</volume>(<issue>6</issue>): <fpage>940</fpage>&#x02013;<lpage>994</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1158/0008-5472.CAN-14-2508">10.1158/0008-5472.CAN-14-2508</ext-link></comment>
<pub-id pub-id-type="pmid">25614516</pub-id></mixed-citation></ref><ref id="pone.0183620.ref089"><label>89</label><mixed-citation publication-type="journal"><name><surname>Stiehl</surname><given-names>T</given-names></name>, <name><surname>Lutz</surname><given-names>C</given-names></name>, <name><surname>Marciniak-Czochra</surname><given-names>A</given-names></name>. <article-title>Emergence of heterogeneity in acute leukemias</article-title>. <source>Biology Direct</source>. <year>2016</year>; <volume>11</volume>: <fpage>51</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s13062-016-0154-1">10.1186/s13062-016-0154-1</ext-link></comment>
<pub-id pub-id-type="pmid">27733173</pub-id></mixed-citation></ref><ref id="pone.0183620.ref090"><label>90</label><mixed-citation publication-type="journal"><name><surname>Goldie</surname><given-names>JH</given-names></name>, <name><surname>Coldman</surname><given-names>AJ</given-names></name>. <article-title>A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate</article-title>. <source>Cancer Treatment Reports</source>. <year>1979</year>; <volume>63</volume>: <fpage>1727</fpage>&#x02013;<lpage>1733</lpage>. <pub-id pub-id-type="pmid">526911</pub-id></mixed-citation></ref><ref id="pone.0183620.ref091"><label>91</label><mixed-citation publication-type="journal"><name><surname>Goldie</surname><given-names>JH</given-names></name>, <name><surname>Coldman</surname><given-names>AJ</given-names></name>. <article-title>Quantitative model for multiple levels of drug resistance in clinical tumors</article-title>. <source>Cancer Treatment Reports</source>. <year>1983</year>; <volume>67</volume>: <fpage>923</fpage>&#x02013;<lpage>931</lpage>. <pub-id pub-id-type="pmid">6627236</pub-id></mixed-citation></ref><ref id="pone.0183620.ref092"><label>92</label><mixed-citation publication-type="journal"><name><surname>Dingli</surname><given-names>D</given-names></name>, <name><surname>Michor</surname><given-names>F</given-names></name>. <article-title>Successful therapy must eradicate cancer stem cells</article-title>. <source>Stem Cells</source>. <year>2006</year>; <volume>24</volume>(<issue>12</issue>): <fpage>2603</fpage>&#x02013;<lpage>2610</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1634/stemcells.2006-0136">10.1634/stemcells.2006-0136</ext-link></comment>
<pub-id pub-id-type="pmid">16931775</pub-id></mixed-citation></ref><ref id="pone.0183620.ref093"><label>93</label><mixed-citation publication-type="journal"><name><surname>De Pillis</surname><given-names>LG</given-names></name> and <name><surname>Radunskaya</surname><given-names>A</given-names></name>: <article-title>The dynamics of an optimal controlled tumor model: a case study</article-title>. <source>Mathematical and computer modelling</source>. <year>2003</year>; <volume>37</volume>: <fpage>1221</fpage>&#x02013;<lpage>1244</lpage>.</mixed-citation></ref><ref id="pone.0183620.ref094"><label>94</label><mixed-citation publication-type="journal"><name><surname>Saleem</surname><given-names>M</given-names></name>, <name><surname>Agrawal</surname><given-names>T</given-names></name>: <article-title>Complex dynamics in a mathematical model of tumor growth with time delays in cell proliferation</article-title>. <source>International Journal of Scientific and Research Publications</source>. <year>2012</year>; <volume>2</volume>(<issue>6</issue>): <fpage>1</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="pone.0183620.ref095"><label>95</label><mixed-citation publication-type="journal"><name><surname>Nielsen</surname><given-names>KH</given-names></name>, <name><surname>Pociot</surname><given-names>FM</given-names></name>, <name><surname>Ottesen</surname><given-names>JT</given-names></name>. <article-title>Bifurcation Analysis of an Existing Mathematical Model Reveals Novel Treatment Strategies and Suggests Potential Cure for Type 1 Diabetes</article-title>. <source>Mathematical Medicine and Biology</source>. <year>2014</year>; <volume>31</volume>(<issue>3</issue>): <fpage>205</fpage>&#x02013;<lpage>225</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/imammb/dqt006">10.1093/imammb/dqt006</ext-link></comment>
<pub-id pub-id-type="pmid">23620354</pub-id></mixed-citation></ref><ref id="pone.0183620.ref096"><label>96</label><mixed-citation publication-type="journal"><name><surname>Baker</surname><given-names>M</given-names></name>, <name><surname>Denman-Johnson</surname><given-names>S</given-names></name>, <name><surname>Brook</surname><given-names>BS</given-names></name>, <name><surname>Gaywood</surname><given-names>I</given-names></name>, <name><surname>Owen</surname><given-names>MR</given-names></name>. <article-title>Mathematical modelling of cytokine-mediated inflammation in rheumatoid arthritis</article-title>. <source>Mathematical Medicine and Biology</source>. <year>2013</year>
<volume>30</volume>: <fpage>311</fpage>&#x02013;<lpage>337</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/imammb/dqs026">10.1093/imammb/dqs026</ext-link></comment>
<pub-id pub-id-type="pmid">23002057</pub-id></mixed-citation></ref><ref id="pone.0183620.ref097"><label>97</label><mixed-citation publication-type="journal"><name><surname>Herald</surname><given-names>MC</given-names></name>. <article-title>General Model of Inflammation</article-title>. <source>Bulletin of Mathematical Biology</source>. <year>2010</year>; <volume>72</volume>: <fpage>765</fpage>&#x02013;<lpage>779</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s11538-009-9468-9">10.1007/s11538-009-9468-9</ext-link></comment>
<pub-id pub-id-type="pmid">19851812</pub-id></mixed-citation></ref><ref id="pone.0183620.ref098"><label>98</label><mixed-citation publication-type="journal"><name><surname>Dunster</surname><given-names>JL</given-names></name>, <name><surname>Byrne</surname><given-names>HM</given-names></name>, <name><surname>King</surname><given-names>JR</given-names></name>. <article-title>The Resolution of Inflammation: A Mathematical Model of Neutrophil and Macrophage Interactions</article-title>. <source>Bull Math Biol</source>. <year>2014</year>; <volume>76</volume>: <fpage>1953</fpage>&#x02013;<lpage>1980</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s11538-014-9987-x">10.1007/s11538-014-9987-x</ext-link></comment>
<pub-id pub-id-type="pmid">25053556</pub-id></mixed-citation></ref><ref id="pone.0183620.ref099"><label>99</label><mixed-citation publication-type="journal"><name><surname>Jacquez</surname><given-names>JA</given-names></name>, <name><surname>Simon</surname><given-names>CP</given-names></name>. <article-title>Qualitative Theory of Compartmental Systems</article-title>. <source>SIAM Review</source>. <year>1993</year>; <volume>35</volume>(<issue>1</issue>): <fpage>43</fpage>&#x02013;<lpage>79</lpage>.</mixed-citation></ref><ref id="pone.0183620.ref100"><label>100</label><mixed-citation publication-type="journal"><name><surname>Michor</surname><given-names>F</given-names></name>, <name><surname>Iwasa</surname><given-names>Y</given-names></name>, <name><surname>Nowak</surname><given-names>MA</given-names></name>. <article-title>The age incidence of chronic myeloid leukemia can be explained by a one-mutation model</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2006</year>; <volume>103</volume>: <fpage>14931</fpage>&#x02013;<lpage>14934</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.0607006103">10.1073/pnas.0607006103</ext-link></comment>
<pub-id pub-id-type="pmid">17001000</pub-id></mixed-citation></ref><ref id="pone.0183620.ref101"><label>101</label><mixed-citation publication-type="journal"><name><surname>Jackson</surname><given-names>AL</given-names></name>, <name><surname>Loeb</surname><given-names>LA</given-names></name>. <article-title>The mutation rate and cancer</article-title>. <source>Genetics</source>. <year>1998</year>; <volume>148</volume>: <fpage>1483</fpage>&#x02013;<lpage>1490</lpage>. <pub-id pub-id-type="pmid">9560368</pub-id></mixed-citation></ref><ref id="pone.0183620.ref102"><label>102</label><mixed-citation publication-type="journal"><name><surname>Cooke</surname><given-names>MS</given-names></name>, <name><surname>Evans</surname><given-names>MD</given-names></name>, <name><surname>Dizdaroglu</surname><given-names>M</given-names></name>, <name><surname>Lunec</surname><given-names>J</given-names></name>. <article-title>Oxidative DNA damage: mechanisms, mutation, and disease</article-title>. <source>FASEB J</source>. <year>2003</year>; <volume>17</volume>: <fpage>1195</fpage>&#x02013;<lpage>1214</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1096/fj.02-0752rev">10.1096/fj.02-0752rev</ext-link></comment>
<pub-id pub-id-type="pmid">12832285</pub-id></mixed-citation></ref><ref id="pone.0183620.ref103"><label>103</label><mixed-citation publication-type="journal"><name><surname>Ferguson</surname><given-names>LR</given-names></name>. <article-title>Chronic inflammation and mutagenesis</article-title>. <source>Mutat Res</source>. <year>2010</year>; <volume>690</volume>: <fpage>3</fpage>&#x02013;<lpage>11</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.mrfmmm.2010.03.007">10.1016/j.mrfmmm.2010.03.007</ext-link></comment>
<pub-id pub-id-type="pmid">20223251</pub-id></mixed-citation></ref><ref id="pone.0183620.ref104"><label>104</label><mixed-citation publication-type="journal"><name><surname>Kiraly</surname><given-names>O</given-names></name>, <name><surname>Gong</surname><given-names>G</given-names></name>, <name><surname>Olipitz</surname><given-names>W</given-names></name>, <name><surname>Muthupalani</surname><given-names>S</given-names></name>, <name><surname>Engelward</surname><given-names>BP</given-names></name>. <article-title>Inflammation-Induced Cell Proliferation Potentiates DNA Damage-Induced Mutations in Vivo</article-title>. <source>Plos Genet</source>. <year>2015</year>; <volume>11</volume>(<issue>2</issue>):<fpage>e100490</fpage>.</mixed-citation></ref><ref id="pone.0183620.ref105"><label>105</label><mixed-citation publication-type="journal"><name><surname>King</surname><given-names>KY</given-names></name>, <name><surname>Goodell</surname><given-names>MA</given-names></name>. <article-title>Inflammatory modulation of hematopoietic stem cells: viewing the hematopoietc stem cell as a foundation for the immune response</article-title>. <source>Nat Rev Immmunol</source>. <year>2014</year>; <volume>11</volume>(<issue>10</issue>): <fpage>685</fpage>&#x02013;<lpage>692</lpage>.</mixed-citation></ref><ref id="pone.0183620.ref106"><label>106</label><mixed-citation publication-type="journal"><name><surname>Rockey</surname><given-names>DC</given-names></name>, <name><surname>Bell</surname><given-names>PD</given-names></name>, <name><surname>Hill</surname><given-names>JA</given-names></name>. <article-title>Fibrosis&#x02014;A Common Pathway to Organ Injury and Fibrosis</article-title>. <source>N Engl J Med</source>. <year>2015</year>; <volume>372</volume>: <fpage>1138</fpage>&#x02013;<lpage>1149</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMra1300575">10.1056/NEJMra1300575</ext-link></comment>
<pub-id pub-id-type="pmid">25785971</pub-id></mixed-citation></ref><ref id="pone.0183620.ref107"><label>107</label><mixed-citation publication-type="journal"><name><surname>Dvorak</surname><given-names>HF</given-names></name>. <article-title>Tumors: wounds that do not heal, Similarities between tumor stroma generation and wound healing</article-title>. <source>N Engl J Med</source>. <year>1986</year>; <volume>315</volume>(<issue>26</issue>): <fpage>1650</fpage>&#x02013;<lpage>1659</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJM198612253152606">10.1056/NEJM198612253152606</ext-link></comment>
<pub-id pub-id-type="pmid">3537791</pub-id></mixed-citation></ref><ref id="pone.0183620.ref108"><label>108</label><mixed-citation publication-type="journal"><name><surname>Dvorak</surname><given-names>HF</given-names></name>. <article-title>Tumors: wounds that do not heal-redux</article-title>. <source>Cancer Immunology Research</source>. <year>2015</year>; <volume>3</volume>(<issue>1</issue>): <fpage>1</fpage>&#x02013;<lpage>11</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1158/2326-6066.CIR-14-0209">10.1158/2326-6066.CIR-14-0209</ext-link></comment>
<pub-id pub-id-type="pmid">25568067</pub-id></mixed-citation></ref><ref id="pone.0183620.ref109"><label>109</label><mixed-citation publication-type="journal"><name><surname>Nikas</surname><given-names>JB</given-names></name>. <article-title>Inflammation and Immune System Activation in Aging: A Mathematical Approach</article-title>. <source>Scientific Reports</source>. <year>2013</year>; <volume>3</volume>: <fpage>3254</fpage>: <fpage>1</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/srep03254">10.1038/srep03254</ext-link></comment>
<pub-id pub-id-type="pmid">24247109</pub-id></mixed-citation></ref><ref id="pone.0183620.ref110"><label>110</label><mixed-citation publication-type="journal"><name><surname>Nielsen</surname><given-names>KH</given-names></name>, <name><surname>Pociot</surname><given-names>FM</given-names></name>, <name><surname>Ottesen</surname><given-names>JT</given-names></name>. <article-title>Bifurcation analysis of an existing mathematical model reveals novel treatment strategies and suggests potential cure for type 1 diabetes</article-title>. <source>Math Med Biol</source>. <year>2014</year>; <volume>31</volume>(<issue>3</issue>): <fpage>205</fpage>&#x02013;<lpage>225</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/imammb/dqt006">10.1093/imammb/dqt006</ext-link></comment>
<pub-id pub-id-type="pmid">23620354</pub-id></mixed-citation></ref><ref id="pone.0183620.ref111"><label>111</label><mixed-citation publication-type="journal"><name><surname>Lo</surname><given-names>WC</given-names></name>, <name><surname>Martin</surname><given-names>EW</given-names><suffix>Jr</suffix></name>, <name><surname>Hitchcock</surname><given-names>CL</given-names></name>, <name><surname>Friedman</surname><given-names>A</given-names></name>. <article-title>Mathematical model of colitis-associated colon cancer</article-title>. <source>J Theor Biol</source>. <year>2013</year>; <volume>317</volume>: <fpage>20</fpage>&#x02013;<lpage>29</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jtbi.2012.09.025">10.1016/j.jtbi.2012.09.025</ext-link></comment>
<pub-id pub-id-type="pmid">23026764</pub-id></mixed-citation></ref><ref id="pone.0183620.ref112"><label>112</label><mixed-citation publication-type="journal"><name><surname>Pardanani</surname><given-names>A</given-names></name>, <name><surname>Fridley</surname><given-names>BL</given-names></name>, <name><surname>Lasho</surname><given-names>TL</given-names></name>, <name><surname>Gilliland</surname><given-names>DG</given-names></name>, <name><surname>Tefferi</surname><given-names>A</given-names></name>. <article-title>Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders</article-title>. <source>Blood</source>. <year>2008</year>; <volume>111</volume>(<issue>5</issue>): <fpage>2785</fpage>&#x02013;<lpage>2789</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2007-06-095703">10.1182/blood-2007-06-095703</ext-link></comment>
<pub-id pub-id-type="pmid">18006699</pub-id></mixed-citation></ref><ref id="pone.0183620.ref113"><label>113</label><mixed-citation publication-type="journal"><name><surname>Kilpivaara</surname><given-names>O</given-names></name>, <name><surname>Mukherjee</surname><given-names>S</given-names></name>, <name><surname>Schram</surname><given-names>AM</given-names></name>, <name><surname>Wadleigh</surname><given-names>M</given-names></name>, <name><surname>Mullally</surname><given-names>A</given-names></name>, <name><surname>Ebert</surname><given-names>BL</given-names></name>, <etal>et al</etal>
<article-title>A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms</article-title>. <source>Nat Genet</source>. <year>2009</year>; <volume>41</volume>(<issue>4</issue>): <fpage>455</fpage>&#x02013;<lpage>459</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ng.342">10.1038/ng.342</ext-link></comment>
<pub-id pub-id-type="pmid">19287384</pub-id></mixed-citation></ref><ref id="pone.0183620.ref114"><label>114</label><mixed-citation publication-type="journal"><name><surname>Jones</surname><given-names>AV</given-names></name>, <name><surname>Chase</surname><given-names>A</given-names></name>, <name><surname>Silver</surname><given-names>RT</given-names></name>, <name><surname>Oscier</surname><given-names>D</given-names></name>, <name><surname>Zoi</surname><given-names>K</given-names></name>, <name><surname>Wang</surname><given-names>YL</given-names></name>, <etal>et al</etal>: <article-title>JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms</article-title>. <source>Nat Genet</source>. <year>2009</year>; <volume>41</volume>(<issue>4</issue>): <fpage>446</fpage>&#x02013;<lpage>449</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ng.334">10.1038/ng.334</ext-link></comment>
<pub-id pub-id-type="pmid">19287382</pub-id></mixed-citation></ref><ref id="pone.0183620.ref115"><label>115</label><mixed-citation publication-type="journal"><name><surname>Olcaydu</surname><given-names>D</given-names></name>, <name><surname>Harutyunyan</surname><given-names>A</given-names></name>, <name><surname>J&#x000e4;ger</surname><given-names>R</given-names></name>, <name><surname>Berg</surname><given-names>T</given-names></name>, <name><surname>Gisslinger</surname><given-names>B</given-names></name>, <name><surname>Pabinger</surname><given-names>I</given-names></name>, <etal>et al</etal>: <article-title>A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms</article-title>. <source>Nat Genet</source>. <year>2009</year>; <volume>41</volume>(<issue>4</issue>): <fpage>450</fpage>&#x02013;<lpage>454</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ng.341">10.1038/ng.341</ext-link></comment>
<pub-id pub-id-type="pmid">19287385</pub-id></mixed-citation></ref><ref id="pone.0183620.ref116"><label>116</label><mixed-citation publication-type="journal"><name><surname>Cross</surname><given-names>NC</given-names></name>. <article-title>Genetic and epigenetic complexity in myeloproliferative neoplasms</article-title>. <source>Hematology Am Soc Hematol Educ Program</source>. <year>2011</year>; <fpage>208</fpage>&#x02013;<lpage>214</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/asheducation-2011.1.208">10.1182/asheducation-2011.1.208</ext-link></comment>
<pub-id pub-id-type="pmid">22160036</pub-id></mixed-citation></ref><ref id="pone.0183620.ref117"><label>117</label><mixed-citation publication-type="journal"><name><surname>Tapper</surname><given-names>W</given-names></name>, <name><surname>Jones</surname><given-names>AV</given-names></name>, <name><surname>Kralovics</surname><given-names>R</given-names></name>, <name><surname>Harutyunyan</surname><given-names>AS</given-names></name>, <name><surname>Zoi</surname><given-names>K</given-names></name>, <name><surname>Leung</surname><given-names>W</given-names></name>, <etal>et al</etal>: <article-title>Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms</article-title>. <source>Nat Commun</source>. <year>2015</year>; <volume>6</volume>: <fpage>6691</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ncomms7691">10.1038/ncomms7691</ext-link></comment>
<pub-id pub-id-type="pmid">25849990</pub-id></mixed-citation></ref><ref id="pone.0183620.ref118"><label>118</label><mixed-citation publication-type="journal"><name><surname>Barrett</surname><given-names>JC</given-names></name>, <name><surname>Hansoul</surname><given-names>S</given-names></name>, <name><surname>Nicolae</surname><given-names>DL</given-names></name>, <name><surname>Cho</surname><given-names>JH</given-names></name>, <name><surname>Duerr</surname><given-names>RH</given-names></name>, <name><surname>Rioux</surname><given-names>JD</given-names></name>, <etal>et al</etal>: <article-title>Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease</article-title>. <source>Nat Genet</source>. <year>2008</year>; <volume>40</volume>(<issue>8</issue>): <fpage>955</fpage>&#x02013;<lpage>962</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ng.175">10.1038/ng.175</ext-link></comment>
<pub-id pub-id-type="pmid">18587394</pub-id></mixed-citation></ref><ref id="pone.0183620.ref119"><label>119</label><mixed-citation publication-type="journal"><name><surname>Ferguson</surname><given-names>LR</given-names></name>, <name><surname>Han</surname><given-names>DY</given-names></name>, <name><surname>Fraser</surname><given-names>AG</given-names></name>, <name><surname>Huebner</surname><given-names>C</given-names></name>, <name><surname>Lam</surname><given-names>WJ</given-names></name>, <name><surname>Morgan</surname><given-names>AR</given-names></name>, <etal>et al</etal>: <article-title>Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population</article-title>. <source>Mutat Res</source>. <year>2010</year>; <volume>690</volume>(<issue>1&#x02013;2</issue>): <fpage>108</fpage>&#x02013;<lpage>115</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.mrfmmm.2010.01.017">10.1016/j.mrfmmm.2010.01.017</ext-link></comment>
<pub-id pub-id-type="pmid">20109474</pub-id></mixed-citation></ref><ref id="pone.0183620.ref120"><label>120</label><mixed-citation publication-type="journal"><name><surname>Martyre</surname><given-names>MC</given-names></name>, <name><surname>Romquin</surname><given-names>N</given-names></name>, <name><surname>Le Bousse-Kerdiles</surname><given-names>MC</given-names></name>, <name><surname>Chevillard</surname><given-names>S</given-names></name>, <name><surname>Benyahia</surname><given-names>B</given-names></name>, <name><surname>Dupriez</surname><given-names>B</given-names></name>, <etal>et al</etal>
<article-title>Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis</article-title>. <source>Br J Haematol</source>. <year>1994</year>; <volume>88</volume>(<issue>1</issue>): <fpage>9</fpage>&#x02013;<lpage>16</lpage>. <pub-id pub-id-type="pmid">7803262</pub-id></mixed-citation></ref><ref id="pone.0183620.ref121"><label>121</label><mixed-citation publication-type="journal"><name><surname>Tefferi</surname><given-names>A</given-names></name>. <article-title>Myelofibrosis with myeloid metaplasia</article-title>. <source>N Engl J Med</source>. <year>2000</year>; <day>27</day>; <volume>342</volume>(<issue>17</issue>): <fpage>1255</fpage>&#x02013;<lpage>1265</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJM200004273421706">10.1056/NEJM200004273421706</ext-link></comment>
<pub-id pub-id-type="pmid">10781623</pub-id></mixed-citation></ref><ref id="pone.0183620.ref122"><label>122</label><mixed-citation publication-type="journal"><name><surname>Takizawa</surname><given-names>H</given-names></name>, <name><surname>Boettcher</surname><given-names>S</given-names></name>, <name><surname>Manz</surname><given-names>MG</given-names></name>. <article-title>Demand-adapted regulation of early hematopoiesis in infection and inflammation</article-title>. <source>Blood</source>. <year>2012</year>; <volume>119</volume>(<issue>13</issue>): <fpage>2991</fpage>&#x02013;<lpage>3002</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2011-12-380113">10.1182/blood-2011-12-380113</ext-link></comment>
<pub-id pub-id-type="pmid">22246037</pub-id></mixed-citation></ref><ref id="pone.0183620.ref123"><label>123</label><mixed-citation publication-type="journal"><name><surname>Parihar</surname><given-names>A</given-names></name>, <name><surname>Eubank</surname><given-names>TD</given-names></name>, <name><surname>Doseff</surname><given-names>AI</given-names></name>. <article-title>Monocytes and macrophages regulate immunity through dynamic networks of survival and cell death</article-title>. <source>J Innate Immun</source>. <year>2010</year>; <volume>2</volume>: <fpage>204</fpage>&#x02013;<lpage>215</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1159/000296507">10.1159/000296507</ext-link></comment>
<pub-id pub-id-type="pmid">20375558</pub-id></mixed-citation></ref><ref id="pone.0183620.ref124"><label>124</label><mixed-citation publication-type="journal"><name><surname>Leblanc</surname><given-names>R</given-names></name>, <name><surname>Peyruchaud</surname><given-names>O</given-names></name>. <article-title>Metastasis: new functional implications of platelets and megakaryocytes</article-title>. <source>Blood</source>. <year>2016</year>; <volume>128</volume>(<issue>1</issue>): <fpage>24</fpage>&#x02013;<lpage>31</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2016-01-636399">10.1182/blood-2016-01-636399</ext-link></comment>
<pub-id pub-id-type="pmid">27154188</pub-id></mixed-citation></ref><ref id="pone.0183620.ref125"><label>125</label><mixed-citation publication-type="journal"><name><surname>Hasselbalch</surname><given-names>HC</given-names></name>. <article-title>The platelet-cancer loop in myeloproliferative cancer. Is thrombocythemia an enhancer of cancer invasiveness and metastasis in essential thrombocythemia, polycythemia vera and myelofibrosis?</article-title>
<source>Leuk Res</source>. <year>2014</year>; <volume>38</volume>(<issue>10</issue>): <fpage>1230</fpage>&#x02013;<lpage>1236</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.leukres.2014.07.006">10.1016/j.leukres.2014.07.006</ext-link></comment>
<pub-id pub-id-type="pmid">25149709</pub-id></mixed-citation></ref><ref id="pone.0183620.ref126"><label>126</label><mixed-citation publication-type="journal"><name><surname>Hasselbalch</surname><given-names>HC</given-names></name>. <article-title>A new era for IFN-&#x003b1; in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms</article-title>. <source>Expert Rev Hematol</source>. <year>2011</year>; <volume>4</volume>(<issue>6</issue>): <fpage>637</fpage>&#x02013;<lpage>655</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1586/EHM.11.63">10.1586/EHM.11.63</ext-link></comment>
<pub-id pub-id-type="pmid">22077528</pub-id></mixed-citation></ref><ref id="pone.0183620.ref127"><label>127</label><mixed-citation publication-type="journal"><name><surname>Silver</surname><given-names>RT</given-names></name>, <name><surname>Kiladjian</surname><given-names>J-J</given-names></name>, <name><surname>Hasselbalch</surname><given-names>HC</given-names></name>. <article-title>Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis</article-title>. <source>Expert Rev Hematol</source>. <year>2013</year>; <volume>6</volume>(<issue>1</issue>): <fpage>49</fpage>&#x02013;<lpage>58</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1586/ehm.12.69">10.1586/ehm.12.69</ext-link></comment>
<pub-id pub-id-type="pmid">23373780</pub-id></mixed-citation></ref><ref id="pone.0183620.ref128"><label>128</label><mixed-citation publication-type="journal"><name><surname>Rank</surname><given-names>C</given-names></name>, <name><surname>Bjerrum</surname><given-names>O</given-names></name>, <name><surname>Larsen</surname><given-names>T</given-names></name>, <name><surname>Kj&#x000e6;r</surname><given-names>L</given-names></name>, <name><surname>de Stricker</surname><given-names>K</given-names></name>, <name><surname>Riley</surname><given-names>CH</given-names></name>, <etal>et al</etal>: <article-title>Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera</article-title>. <source>Leuk Lymphoma</source>. <year>2015</year>; <fpage>1</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="pone.0183620.ref129"><label>129</label><mixed-citation publication-type="journal"><name><surname>Kiladjian</surname><given-names>JJ</given-names></name>, <name><surname>Giraudier</surname><given-names>S</given-names></name>, <name><surname>Cassinat</surname><given-names>B</given-names></name>. <article-title>Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone</article-title>. <source>Leukemia</source>. <year>2016</year>; <volume>30</volume>(<issue>4</issue>): <fpage>776</fpage>&#x02013;<lpage>781</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/leu.2015.326">10.1038/leu.2015.326</ext-link></comment>
<pub-id pub-id-type="pmid">26601783</pub-id></mixed-citation></ref><ref id="pone.0183620.ref130"><label>130</label><mixed-citation publication-type="journal"><name><surname>Hasselbalch</surname><given-names>HC</given-names></name>. <article-title>Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms</article-title>. <source>Expert Rev Hematol</source>. <year>2014</year>; <volume>7</volume>(<issue>2</issue>): <fpage>203</fpage>&#x02013;<lpage>216</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1586/17474086.2013.876356">10.1586/17474086.2013.876356</ext-link></comment>
<pub-id pub-id-type="pmid">24524202</pub-id></mixed-citation></ref></ref-list></back></article>